NOFOs & Notices

Advancing Vision Health Equity through Multi-level Interventions and Community-Engaged Research (R01 - Clinical Trial Optional), RFA-EY-25-002, National Eye Institute (NEI), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 12/30/24

D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional), PAS-25-236, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Posted on 12/16/24

Risk and Protective Factors of Family Health and Family Level Interventions (R01 Clinical Trial Optional), PAR-25-317, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Nursing Research (NINR), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH), Sexual and Gender Minority Research Office (SGMRO), Tribal Health Research Office (THRO)
Posted on 12/13/24

Limited Competition: Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial Optional), RFA-MD-24-011, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH)
Posted on 12/9/24

Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional), PAR-24-330, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), Office of Behavioral and Social Sciences Research (OBSSR)
Posted on 12/6/24

Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed), RFA-DA-26-055, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Posted on 12/5/24

Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed), RFA-DA-26-056, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Posted on 12/5/24

High-Priority Research in Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-25-001, Office of Disease Prevention (ODP), National Institutes of Health (NIH), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Drug Abuse (NIDA)
Posted on 12/5/24

Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional), PAR-25-299, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 12/5/24

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional), PAR-25-242, Fogarty International Center (FIC), National Institutes of Health (NIH), National Cancer Institute (NCI), National Eye Institute (NEI), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Mental Health (NIMH), Office of Dietary Supplements (ODS), Office of Research on Women's Health (ORWH)
Posted on 12/4/24

Accelerating Solutions to Improve Access and Quality of Empirically-Supported Practices for Youth Mental Health (R01 Clinical Trial Optional), PAR-25-310, National Institute of Mental Health (NIMH), National Institutes of Health (NIH)
Posted on 12/3/24

Research to Address Systemic and Structural Barriers and Facilitators to Improve the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum for People Who Use Substances (R01 Clinical Trials Required), RFA-DA-26-003, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), Office of AIDS Research (OAR), Office of Research on Women's Health (ORWH)
Posted on 12/2/24

Translational Neural Devices (R61/R33 - Clinical Trial Optional), PAR-25-053, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Posted on 10/29/24

Environmental Health Disparities Centers (P50) Clinical Trial Optional, RFA-MD-24-010, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), Environmental Influences on Child Health Outcomes (ECHO), National Cancer Institute (NCI), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), National Institute of Nursing Research (NINR)
Posted on 10/21/24

HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional), RFA-NS-25-020, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA)
Posted on 10/8/24

Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional), PAR-24-273, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), National Institute of Nursing Research (NINR), Office of Disease Prevention (ODP), National Cancer Institute (NCI), National Institute on Aging (NIA)
Posted on 8/27/24

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional), RFA-DA-25-024, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Posted on 8/2/24

Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations II (U01 Clinical Trial Not Allowed), PAR-24-240, National Institute of Mental Health (NIMH), National Institutes of Health (NIH)
Posted on 7/10/24

Limited Competition: Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional, RFA-HG-24-026, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH)
Posted on 7/10/24

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional), PAR-25-158, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH)
Posted on 11/25/24

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional), PAR-25-159, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), Office of Disease Prevention (ODP)
Posted on 11/25/24

The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional), PAR-25-292, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH)
Posted on 11/25/24

Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional), PAR-25-278, National Institute of Mental Health (NIMH), National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 11/21/24

Advancing Genomic Medicine Research (R01 Clinical Trial Optional), RFA-HG-25-002, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), National Cancer Institute (NCI)
Posted on 11/19/24

Advancing Genomic Medicine Research (R21 Clinical Trial Optional), RFA-HG-25-003, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), National Cancer Institute (NCI)
Posted on 11/19/24

Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed), RFA-HG-25-004, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH)
Posted on 11/19/24

NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required), PAR-25-049, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Posted on 11/7/24

Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional), PAR-25-117, National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), National Eye Institute (NEI), National Human Genome Research Institute (NHGRI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), Tribal Health Research Office (THRO)
Posted on 11/6/24

Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional), RFA-MD-24-012, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH)
Posted on 9/13/24

Limited Competition: NIMHD Initiative for Improving American Indian and Alaska Native Cancer Outcomes (U19 - Clinical Trial Optional), RFA-MD-24-009, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 6/17/24

Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional), PAR-24-231, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 6/10/24

Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions (P50 Clinical Trial Optional), RFA-HD-25-002, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 6/7/24

Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional), PAR-24-207, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI)
Posted on 5/13/24

Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Optional), RFA-MH-25-185, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), Office of AIDS Research (OAR), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 4/29/24

Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional), RFA-MH-25-186, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), Office of AIDS Research (OAR), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Drug Abuse (NIDA)
Posted on 4/29/24

Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional), PAR-24-110, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Cancer Institute (NCI), Office of Behavioral and Social Sciences Research (OBSSR)
Posted on 4/19/24

Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical Trial Required), RFA-MH-25-130, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 4/17/24

Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional), RFA-MH-25-190, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 4/3/24

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed), PAR-24-162, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 3/18/24

Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed), RFA-MD-24-005, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Sexual and Gender Minority Research Office (SGMRO)
Posted on 3/1/24

Translational Neural Devices (R61/R33 - Clinical Trial Optional), PAR-24-151, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 2/23/24

Limited Competition: Collaborative Study on the Genetics of Alcoholism (COGA) (U10 Clinical Trial Not Allowed), RFA-AA-24-003, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 2/14/24

Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional), PAR-24-118, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA)
Posted on 2/8/24

High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional), RFA-DA-25-060, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 1/17/24

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional), PAR-23-318, National Institutes of Health (NIH), Fogarty International Center (FIC), National Eye Institute (NEI), National Background Investigation Bureau, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Mental Health (NIMH), National Cancer Institute (NCI), Office of Dietary Supplements (ODS), Office of Research on Women's Health (ORWH)
Posted on 12/6/23

Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional), PAR-24-077, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Office of Behavioral and Social Sciences Research (OBSSR), Sexual and Gender Minority Research Office (SGMRO)
Posted on 11/30/23

Coordinating Center to Support Multi-Sectoral Preventive Interventions that Address Social Determinants of Health in Populations that Experience Health Disparities (U24, Clinical Trial Not Allowed), RFA-OD-24-006, National Institutes of Health (NIH), Office of Disease Prevention (ODP), National Institute on Minority Health and Health Disparities (NIMHD), Office of Data Science Strategy (ODSS)
Posted on 7/5/24

Multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities (UG3/UH3, Clinical Trial Required), PAR-24-053, National Institutes of Health (NIH), Office of Disease Prevention (ODP), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), Office of Dietary Supplements (ODS), Sexual and Gender Minority Research Office (SGMRO), Office of Research on Women's Health (ORWH)
Posted on 7/5/24

The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required), RFA-DA-25-027, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 2/13/24

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional), PAR-24-067, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 1/16/24

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional), PAR-24-068, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 1/16/24

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional), RFA-NS-24-019, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 10/31/23

Career Enhancement Award to Advance Research on Firearm Injury and Mortality Prevention (K18 Independent Clinical Trial Not Allowed}, PAR-24-070, Office of Behavioral and Social Sciences Research (OBSSR), National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH), Sexual and Gender Minority Research Office (SGMRO)
Posted on 11/24/23

Career Enhancement Award to Advance Research on Firearm Injury and Mortality Prevention (K18 Independent Clinical Trial Required), PAR-24-073, Office of Behavioral and Social Sciences Research (OBSSR), National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR), Office of Disease Prevention (ODP), Sexual and Gender Minority Research Office (SGMRO)
Posted on 11/24/23

Advancing Genomic Medicine Research (R01 Clinical Trial Optional), RFA-HG-23-032, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI)
Posted on 11/6/23

Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed), RFA-HG-23-048, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)
Posted on 11/6/23

Advancing Genomic Medicine Research (R21 Clinical Trial Optional), RFA-HG-23-033, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI)
Posted on 11/6/23

Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional), PAR-23-293, National Institutes of Health (NIH), Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI), National Eye Institute (NEI), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI), National Institute on Minority Health and Health Disparities (NIMHD), Office of Research on Women's Health (ORWH)
Posted on 10/30/23

Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional), PAR-23-295, National Institutes of Health (NIH), Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Cancer Institute (NCI), Office of Data Science Strategy (ODSS), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women's Health (ORWH)
Posted on 10/30/23

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional), PAR-23-294, National Institutes of Health (NIH), Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI), National Eye Institute (NEI), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women's Health (ORWH)
Posted on 10/30/23

Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional), PAR-24-059, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH)
Posted on 8/11/23

Comprehensive Alcohol-HIV/AIDS Research Center (P60 Clinical Trial Optional), RFA-AA-23-004, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 8/10/23

Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required), RFA-MD-24-003, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), Sexual and Gender Minority Research Office (SGMRO), Office of Research on Women's Health (ORWH)
Posted on 8/1/23

HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R01 Clinical Trial Optional), RFA-AA-23-005, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 11/14/23

HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R34 Clinical Trial Optional), RFA-AA-23-006, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 11/14/23

Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional), RFA-MD-24-001, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 10/17/23

HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional), RFA-NS-24-021, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 10/7/23

Career Enhancement Award to Advance the Study of Intimate Partner Violence (IPV) in the Context of Maternal Morbidity and Mortality Research (K18 Clinical Trial Not Allowed), RFA-OD-24-001, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Nursing Research (NINR), Sexual and Gender Minority Research Office (SGMRO), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH)
Posted on 10/4/23

Community-Engaged Health Equity Research in Neuroscience Initiative (R34 CT Not Allowed), RFA-NS-24-007, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 9/4/23

Community-Engaged Health Equity Research in Neuroscience Initiative (R01 CT Not Allowed), RFA-NS-24-006, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 9/4/23

Public Health Communication Messaging about the Continuum of Risk for Tobacco Products (U01 Clinical Trial Required), RFA-OD-23-021, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Office of Disease Prevention (ODP), National Cancer Institute (NCI)
Posted on 8/2/23

Network of Genomics-Enabled Learning Health Systems (gLHS) - Coordinating Center (U01 Clinical Trials Required), RFA-HG-23-042, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)
Posted on 8/1/23

Network of Genomics-Enabled Learning Health Systems (gLHS) - Clinical Sites (U01 Clinical Trial Required), RFA-HG-23-041, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)
Posted on 8/1/23

HEAL Initiative: Toward Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required), RFA-AT-24-003, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)
Posted on 6/9/23

Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional), RFA-HG-23-017, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Cancer Institute (NCI)
Posted on 6/5/23

Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional), RFA-HG-23-018, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA)
Posted on 6/5/23

Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional), RFA-MH-24-120, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 6/2/23

Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors – Clinical Centers (U01 Clinical Trial Not Allowed), RFA-DK-23-010, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 5/15/23

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-23-017, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Cancer Institute (NCI)
Posted on 5/4/23

Emergency Award: RADx-®UP Dissemination and Implementation (D&I) Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations (R01 Clinical Trial Optional), RFA-OD-23-051, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 5/2/23

HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional), RFA-NS-23-028, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 4/27/23

Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed), RFA-TR-23-011, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 4/20/23

Advancing Integrated Models (AIM) of Care to Improve Pregnancy Outcomes among Women Who Experience Persistent Disparities (R01 Clinical Trial Optional), RFA-NR-23-002, National Institutes of Health (NIH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 2/27/23

Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional), RFA-MD-23-004, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 2/15/23

Pilot Interventions to Integrate Social Care and Medical Care to Improve Health Equity (R01 Clinical Trial Required), RFA-DK-22-038, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 2/13/23

NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required), PAR-23-090, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 2/8/23

Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional), RFA-DA-24-037, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 2/7/23

Career Enhancement Award to Advance Research on Firearm Injury and Mortality Prevention (K18 Independent Clinical Trial Not Allowed), PAR-23-108, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/30/23

Career Enhancement Award to Advance Research on Firearm Injury and Mortality Prevention (K18 Independent Clinical Trial Required), PAR-23-107, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/30/23

Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 – Clinical Trial Optional), PAR-23-112, National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Minority Health and Health Disparities (NIMHD), National Eye Institute (NEI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/31/23

Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required), RFA-MH-23-170, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 1/12/23

NIDA Program Project Grant Applications (P01 Clinical Trial Optional), PAR-23-064, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 1/8/23

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required), RFA-NS-23-012, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), Office of The Director, National Institutes of Health (OD)
Posted on 1/9/23

Research Centers in Minority Institutions (RCMI) (U54 Clinical Trial Optional), RFA-MD-23-001, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 12/30/22

Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (UG3/UH3 Clinical Trial Required), PAR-23-066, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), Sexual and Gender Minority Research Office (SGMRO)
Posted on 12/14/22

Interventions that Address Structural Racism to Reduce Kidney Health Disparities - Research Coordinating Center (U24 - Clinical Trial Not Allowed), RFA-DK-23-003, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 11/18/22

HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional), RFA-DA-23-059, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI)
Posted on 11/15/22

HEAL Initiative - Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program: Leadership and Data Co-ordinating Center (U01 Clinical Trial Optional), RFA-DA-23-060, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI)
Posted on 11/15/22

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed), RFA-DA-24-002, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 11/15/22

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required), RFA-OD-22-026, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)
Posted on 11/10/22

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed), RFA-OD-22-025, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)
Posted on 11/10/22

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required), RFA-OD-22-024, , National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)
Posted on 11/10/22

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed), RFA-OD-22-023, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)
Posted on 11/10/22

HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional), RFA-NS-22-069, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 11/4/22

Community Partnerships to Advance Science for Society (ComPASS): Coordination Center (U24 Clinical Trial Optional), RFA-RM-23-001, National Institutes of Health (NIH), Office of Strategic Coordination (Common Fund)
Posted on 10/3/22

Advancing Adolescent Tobacco Cessation Intervention Research (R34 Clinical Trial Optional), RFA-CA-22-042, National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA)
Posted on 10/3/22

Advancing Adolescent Tobacco Cessation Intervention Research (R01 Clinical Trial Required), RFA-CA-22-043, National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA)
Posted on 10/3/22

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional), RFA-DA-23-061, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 10/4/22

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional), RFA-DA-23-062, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 10/4/22

HEAL Initiative: HEAL Data2Action – Acceleration Projects (R33 Clinical Trial Not Allowed), RFA-DA-23-058, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 9/21/22

HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards (R61/R33, Clinical Trial Optional), RFA-DA-23-057, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 9/21/22

HEAL Initiative: Prevention and Management of Chronic Pain in Rural Populations (UG3/UH3, Clinical Trials Required), RFA-NR-23-001, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health Sciences (NIEHS), National Cancer Institute (NCI), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)
Posted on 9/16/22

Limited Competition: The NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL) (U24 Clinical Trial Not Allowed), RFA-HG-22-020, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)
Posted on 9/16/22

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-22-202, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)National Institute on Drug Abuse (NIDA)
Posted on 9/1/22

Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional), PAR-22-200, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 9/1/22

Environmental influences on Child Health Outcomes (ECHO) Data Analysis Center (U24 Clinical Trial Not Allowed), RFA-OD-22-022, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS)
Posted on 8/30/22

Environmental influences on Child Health Outcomes (ECHO) Measurement Core (U24 Clinical Trial Not Allowed), RFA-OD-22-020, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS)
Posted on 8/30/22

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R21 Basic Experimental Studies with Humans Required), RFA-HD-23-033, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/29/22

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R21 Clinical Trial Not Allowed), RFA-HD-23-031, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/29/22

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Clinical Trial Not Allowed), RFA-HD-23-030, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/29/22

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Basic Experimental Studies with Humans Required), RFA-HD-23-032, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/29/22

HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed), RFA-EB-22-002, National Institutes of Health (NIH), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 8/23/22

HEAL Initiative: Development and validation of virtual assessments to study children and caregivers in their natural environment (R01- Clinical Trial Not Allowed), RFA-DA-23-050, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/18/22

HEAL Initiative: Development and validation of virtual assessments to study children and caregivers in their natural environment (R01- Basic Experimental Studies with Humans Required), RFA-DA-23-055, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/18/22

Maternal Health Research Centers of Excellence Data Innovation and Coordinating Hub/Resource Center (U24 Clinical Trial Not Allowed), RFA-HD-23-036, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Office of AIDS Research (OAR), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), Sexual and Gender Minority Research Office (SGMRO)
Posted on 8/11/22

AD/ADRD, Adverse Childhood Experiences, and Social Determinants of Health Ancillary Studies of Existing Longitudinal Cohorts (R01 - Clinical Trial Not Allowed), PAR-22-221, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA)
Posted on 8/10/22

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional), RFA-DA-23-032, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional), RFA-DA-23-031, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional), RFA-DA-23-029, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional), RFA-DA-23-028, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional), RFA-DA-23-026, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Coordination Center to Support Racial Equity and Substance Use Disparities Research (U24 Clinical Trial Not Allowed), RFA-DA-23-025, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional), RFA-DA-23-024, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional), RFA-DA-23-023, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional), RFA-DA-23-013, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed), RFA-NS-22-070, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 8/9/22

HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R21 Clinical Trial Not Allowed), RFA-DE-23-016, National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/3/22

HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R01 Clinical Trial Not Allowed), RFA-DE-23-015, National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/3/22

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional), RFA-DA-23-054, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/3/22

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional), RFA-DA-23-053, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/3/22

HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional), RFA-NS-23-003, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 8/1/22

Interventions that Address Structural Racism to Reduce Kidney Health Disparities - (U01 - Clinical Trial Required), RFA-DK-22-014, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 7/27/22

Interventions that Address Structural Racism to Reduce Kidney Health Disparities - Research Coordinating Center (U24 - Clinical Trial Not Allowed), RFA-DK-22-015, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 7/27/22

HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers (R61/R33 Clinical Trial Required), RFA-DA-23-048, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 7/26/22

NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems (UG3/UH3 - Clinical Trial Optional), RFA-NS-22-053, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 7/21/22

HEAL Initiative: Coordinated Pain Care in Health Care Systems Research Program - Coordinating Center (U24 Clinical Trial Not Allowed), RFA-NS-22-065, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 7/21/22

Expanding Collaborative Implementation Science to Address Social and Structural Determinants of Health and Improve HIV Outcomes (R01 Clinical Trial Required), RFA-MH-22-190, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA)
Posted on 7/20/22

Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional), PAR-22-210, National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 7/15/22

HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required), PAS-22-206, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 7/14/22

HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required), PAS-22-207, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 7/14/22

HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required), RFA-AT-23-002, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Advancing Translational Sciences (NCATS)
Posted on 7/13/22

HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional), RFA-AT-23-001, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 7/13/22

HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 - Clinical Trials Optional), RFA-DA-23-051, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Posted on 7/13/22

Understanding the Pathophysiology and Clinical Course of New-Onset Diabetes Following COVID-19 (U01 Clinical Trial Not Allowed), RFA-DK-22-016, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 7/13/22

HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL) (R01 Clinical Trial Required), RFA-DA-23-041, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 7/11/22

HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL): Resource Center (U24- Clinical Trial Optional), RFA-DA-23-042, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 7/11/22

New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI): Clinical/Community Field Centers (UG3/UH3 - Clinical Trial Not Allowed), RFA-HL-23-015, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH)
Posted on 7/6/22

HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed), RFA-DA-23-045, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 7/7/22

HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On (RM1 - Clinical Trial Optional), RFA-DA-23-046, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 7/6/22

Enabling SUD Digital Therapeutics Research to Improve Payor Adoption (R44- Clinical Trial Only), RFA-DA-23-018, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/29/22

NIDA Program Project Grant Applications (P01 Clinical Trial Optional), PAR-22-201, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/29/22

Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed), RFA-DA-23-017, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/23/22

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed), RFA-DA-23-052, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/14/22

Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional), RFA-DA-23-020, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/10/22

Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional), RFA-DA-23-019, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/10/22

Stakeholder Engagement Innovation Center for Advancing Health Equity in Type 2 Diabetes Research (U2C - Clinical Trial Not Allowed), RFA-DK-22-001, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 6/10/22

Data Management Coordinating Center for Diagnostic Centers of Excellence (U2C Clinical Trial Not Allowed), RFA-NS-22-051, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Human Genome Research Institute (NHGRI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Posted on 6/6/22

Research Coordinating Center to Support Climate Change and Health Community of Practice (U24 - Clinical Trial Not Allowed), RFA-ES-22-003, National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), Fogarty International Center (FIC), National Cancer Institute (NCI)
Posted on 6/6/22

NINDS Interdisciplinary Team Science Grant (RM1 Clinical Trial Optional), RFA-NS-22-036, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 5/18/22

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required), RFA-NS-22-071, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), Office of The Director, National Institutes of Health (OD)
Posted on 5/12/22

Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional), PAR-22-182, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/9/22

Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional), PAR-22-183, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/9/22

Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional), PAR-22-167, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of General Medical Sciences (NIGMS), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 5/9/22

Emergency Awards: HEAL Initiative: Coordinating Center for National Pain Scientists Career Development (R24 Clinical Trial Not Allowed), RFA-NS-22-060, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH)
Posted on 5/5/22

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed), RFA-DA-23-040, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 4/26/22

HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed), RFA-NS-22-052, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 4/22/22

Small Research Grants for Analysis, Curation, and/or Sharing of Down syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed), RFA-OD-22-008, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)
Posted on 4/8/22

Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required), RFA-DA-23-002, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 4/6/22

Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required), RFA-OD-22-010, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)
Posted on 4/5/22

Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed), RFA-OD-22-009, National Institutes of Health (NIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)
Posted on 4/5/22

INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed), RFA-OD-22-007, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)
Posted on 4/5/22

Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional), PAR-22-145, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Mental Health (NIMH), National Library of Medicine (NLM)
Posted on 3/31/22

Implementation Research to Reduce Noncommunicable Disease (NCD) Burden in Low- and Middle-Income Countries (LMICs) and Tribal Nations During Critical Life Stages and Key Transition Periods (R01 Clinical Trial Optional), PAR-22-132, National Institutes of Health (NIH), Fogarty International Center (FIC), National Eye Institute (NEI), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)
Posted on 3/30/22

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional), RFA-DA-23-021, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/28/22

Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional), RFA-MD-22-008, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)
Posted on 3/22/22

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed), PAR-22-138, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 3/15/22

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed), PAR-22-137, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 3/15/22

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional), PAR-22-133, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/15/22

Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R21 - Clinical Trial Not Allowed), RFA-DA-23-009, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/14/22

Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R34 - Clinical Trial Optional), RFA-DA-23-010, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/14/22

Addressing Mental Health Disparities Research Gaps: Aggregating and Mining Existing Data Sets for Secondary Analyses (R01 Clinical Trial Not Allowed), RFA-MH-22-200, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/11/22

Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54 Clinical Trial Optional), RFA-OD-22-004, National Institutes of Health (NIH), , U.S. Food and Drug Administration (FDA), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS)
Posted on 3/8/22

Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54 Clinical Trial Not Allowed), RFA-OD-22-003, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA)
Posted on 3/8/22

Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (UG3/UH3 Clinical Trial Optional), PAR-22-115, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 3/4/22

Coordinating Center to Support Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (U24 Clinical Trial Not Allowed), PAR-22-120, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 3/4/22

Limited Competition for the Continuation of the Data Coordinating Center for the Diabetic Foot Consortium (U24 Clinical Trial Optional), RFA-DK-21-505, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 3/3/22

Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 Clinical Trial Required), RFA-DA-23-006, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 2/25/22

Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R34 Clinical Trial Required), RFA-DA-23-007, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 2/25/22

Emergency Awards: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trial Optional), RFA-OD-22-005, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 2/17/22

Emergency Award: RADx-UP Community-Engaged Research on Rapid SARS-CoV-2 Testing among Underserved and Vulnerable Populations (U01 Clinical Trial Optional), RFA-OD-22-006, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 2/17/22

Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 Clinical Trial Optional), RFA-DA-23-003, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 2/11/22

HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional), RFA-NS-22-050, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 2/8/22

HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed), RFA-NS-22-018, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 2/4/22

HEAL Initiative: Human Pain-associated Genes & Cells Data Coordination and Integration Center (U24 Clinical Trial Not Allowed), RFA-NS-22-021, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 2/1/22

Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required), PAR-22-112, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 1/31/22

Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Optional), PAR-22-113, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 1/31/22

Advancing Integrated Models (AIM) of Care to Improve Maternal Health Outcomes among Women Who Experience Persistent Disparities (R01 Clinical Trial Required), RFA-NR-22-002, National Institutes of Health (NIH), National Institute of Nursing Research (NINR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 1/26/22

HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed), RFA-DE-22-011, National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 1/21/22

Emergency Award HEAL Initiative: Optimizing Existing Evidence-Based Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional), RFA-MH-22-175, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/21/22

Emergency Award HEAL Initiative: Developing and Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional), RFA-MH-22-176, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/21/22

Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed), RFA-TR-22-013, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 1/20/22

HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required), RFA-NS-22-037, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 1/20/22

Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 Clinical Trial Optional), RFA-MD-22-007, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH)
Posted on 1/20/22

Emergency Awards: HEAL Initiative-Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Research Network (ERN) (U24 Clinical Trial Not Allowed), RFA-TR-22-012, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH), National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/19/22

Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional), RFA-DA-22-038, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 1/10/22

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional), RFA-DA-22-037, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 1/10/22

HEAL Initiative: National K12 Clinical Pain Career Development Program (K12 Clinical Trial Not Allowed), RFA-NS-22-045, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 1/10/22

HEAL Initiative: Coordinating Center for National Pain Scientists Career Development (R24 Clinical Trial Not Allowed), RFA-NS-22-046, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/10/22

HEAL Initiative: Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN) (UC2 Clinical Trial Not Allowed), RFA-AR-22-009, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/10/22

HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed), RFA-NS-22-034, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 1/7/22

HEAL Initiative: HEAL Data2Action Modeling and Economic Resource Center (U24 Clinical Trial Optional), RFA-DA-049, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/30/21

HEAL Initiative: HEAL Data2Action Research Adoption Support Center (U2C Clinical Trial Optional), RFA-DA-22-050, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/30/21

HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional), RFA-DA-22-051, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/30/21

HEAL Initiative: Pilot & Feasibility Trials to Improve Prevention and Treatment Service Delivery for Polysubstance Use (R34 Clinical Trial Optional), RFA-DA-22-048, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/29/21

HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional), RFA-DA-22-047, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/29/21

HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional), RFA-DA-22-046, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/29/21

HEAL Initiative: Research Networks for the Study of Recovery Support Services for Persons Treated with Medications for Opioid Use Disorder (R24 Clinical Trial Optional), RFA-DA-22-043, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/29/21

HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders: Coordination Center (R24 Clinical Trial Optional), RFA-DA-22-042, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Posted on 12/29/21

HEAL Initiative: Planning Grants for Efficacy or Effectiveness Trials of Recovery Support Services for Individuals Treated with Medications for Opioid Use Disorder (R34 Clinical Trial Optional), RFA-DA-22-034, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/29/21

HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed), RFA-DA-22-045, National Institutes of Health, National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/20/21

HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed), RFA-DA-22-044, National Institutes of Health, National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/20/21

Center for Rapid Surveillance of Tobacco (CRST) to Assess Changes in Use Behaviors, Product Marketing, and the Marketplace (U01 Clinical Trial Not Allowed), RFA-OD-22-002, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), National Cancer Institute (NCI)
Posted on 12/13/21

Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional), PAR-21-358, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR), National Cancer Institute (NCI)
Posted on 12/13/21

Research Centers in Minority Institutions (RCMI) (U54 Clinical Trials Optional), RFA-MD-22-002, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 11/23/21

NIH HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 Clinical Trials Optional), RFA-DA-22-036, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Mental Health (NIMH)
Posted on 11/16/21

Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities (R01 Clinical Trial Optional), PAR-22-064, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Deafness and Other Communication Disorders (NIDCD)
Posted on 11/16/21

Understanding Place-Based Health Inequalities in Mid-Life (R01 Clinical Trial Not Allowed), RFA-AG-23-004, National Institutes of Health (NIH)
Posted on 11/16/21

HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required), RFA-AT-22-003, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS)
Posted on 11/16/21

Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required), RFA-MH-22-150, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 11/15/21

Home and Community-Based Physical Activity Interventions to Improve the Health of Wheelchair Users (R01 Clinical Trial Required), RFA-HD-22-017, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Posted on 10/29/21

HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required), RFA-AT-22-005, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Advancing Translational Sciences (NCATS)
Posted on 10/29/21

HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional), RFA-AT-22-004, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 10/29/21

Clinical Research Education and Career Development (CRECD) Program (R25-Independent Clinical Trial Not Allowed), PAR-21-347, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Nursing Research (NINR)
Posted on 10/19/21

NIH Health Care Systems Research Collaboratory - Pragmatic and Implementation Trials of Embedded Interventions (UG3/UH3, Clinical Trials Optional), RFA-AT-22-001, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 10/18/21

HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required), RFA-NS-22-002, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 10/8/21

Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional), RFA-ES-21-007, National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS)
Posted on 10/6/21

Pediatric Obesity Discovery Science Research to Improve Understanding of Risk and Causal Mechanisms for Obesity in Early Life (R01 Clinical Trial Optional), RFA-DK-21-025, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 10/4/21

HEAL initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression Without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development) (UG3/UH3 Clinical Trials Not Allowed), RFA-HL-22-013, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA)
Posted on 9/30/21

Investigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Exploratory/Developmental Research Grant Award (R21 Clinical Trial Not Allowed), RFA-OD-21-007, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP), National Cancer Institute (NCI)
Posted on 9/24/21

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional), PAS-21-270, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 9/10/21

An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immunogenicity in Severe Hemophilia A: Hemophilia A Analytical Cohort Research Program (UG3/UH3 Clinical Trial Not Allowed), RFA-HL-22-004, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Posted on 9/9/21

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional), RFA-DA-22-040, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 9/8/21

Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R01 - Clinical Trial Optional), RFA-DA-22-028, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 9/8/21

Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R21 - Clinical Trial Optional), RFA-DA-22-039, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 9/8/21

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional), PAR-22-027, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 9/3/21

HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional), RFA-NS-22-016, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS)
Posted on 8/31/21

Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional), RFA-DA-22-022, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/12/21

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional), PAR-21-303, National Institutes of Health (NIH)
Posted on 8/4/21

Imaging - Science Track Award for Research Transition (I/START) (R03- Basic Experimental Studies with Humans Required), PAR-21-309, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/2/21

Imaging - Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional), PAR-21-310, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/2/21

Advancing Validated Drug Targets for Substance Use Disorders (R41/R42 - Clinical Trial Not Allowed), RFA-DA-22-018, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 7/29/21

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed), RFA-DA-22-033, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 7/21/21

Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional), RFA-DA-23-001, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 7/9/21

HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed), RFA-DA-22-032, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 7/6/21

HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed), RFA-DA-22-031, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 7/6/21

Exploratory Studies to Investigate the Mechanisms of Interrelationship between Sleep and Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans Required), RFA-DA-22-029, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/28/21

The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional), PAR-21-275, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Cancer Institute (NCI)
Posted on 6/25/21

Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R34 Clinical Trial Required), RFA-MH-21-241, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 6/25/21

Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R01 Clinical Trial Required), RFA-MH-21-240, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 6/25/21

Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 - Clinical Trials Not Allowed), RFA-DA-22-003, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/23/21

Large Scale Mapping and/or Molecular Profiling of Ensembles and/or Cell-Types Mediating Opioid Action in the Rodent Brain (R01 - Clinical Trial Not Allowed), RFA-DA-22-011, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/21/21

Organoid Modeling of Neural Stimulants and HIV Comorbidity of Human Brain (R01- Clinical Trial Optional), RFA-DA-22-009, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/17/21

PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional), RFA-DA-22-017, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/16/21

NIDA Animal Genomics Program (U01 - Clinical Trial Not Allowed), PAR-21-244, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/10/21

Exploratory Studies to Investigate the Mechanisms of Interrelationship Between Sleep and Substance Use Disorders (R61/R33 Clinical Trials Not Allowed), RFA-DA-22-016, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/4/21

Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation (R01 Clinical Trial Optional), RFA-DA-22-012, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/24/21

Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Basic Experimental Studies with Humans Required), RFA-DA-22-030, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/24/21

Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Basic Experimental Studies with Humans Required), RFA-DA-22-024, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/24/21

Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 Clinical Trial Not Allowed), RFA-DA-22-007, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/24/21

Mechanistic studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Clinical Trial Not Allowed), RFA-DA-22-005, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/24/21

NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required), PAR-21-237, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 5/19/21

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional), PA-21-180, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 5/19/21

Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required), PA-21-205, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/10/21

Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional), RFA-DA-22-001, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 4/27/21

Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required), RFA-MH-21-230, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 4/19/21

NIMHD Multiple Chronic Disease Disparities Research Coordinating Center (RCC) (U24 Clinical Trial Not Allowed), RFA-MD-21-008, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 4/14/21

Centers for Multiple Chronic Diseases Associated with Health Disparities: Prevention, Treatment, and Management (P50 Clinical Trial Required), RFA-MD-21-007, National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 4/14/21

Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional), RFA-OD-21-009, National Institutes of Health (NIH)
Posted on 4/13/21

Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations - RADx-UP Phase II (U01 Clinical Trial Optional), RFA-OD-21-008, National Institutes of Health (NIH)
Posted on 4/13/21

Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed), RFA-DA-22-021, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 4/8/21

Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R43/R44 - Clinical Trial Not Allowed), RFA-DA-22-019, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 4/8/21

Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed), PAR-21-213, National Institutes of Health (NIH) National Institute on Aging (NIA), National Eye Institute (NEI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 4/6/21

Limited Competition Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed), RFA-DA-22-002, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 4/2/21

Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional), PAR-21-208, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/26/21

Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional), PAR-21-183, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/23/21

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional), RFA-MD-21-004, National Institutes of Health (NIH)
Posted on 3/23/21

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required), PAR-21-132, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 3/2/21

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-21-002, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA)
Posted on 2/17/21

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed), RFA-AA-21-003, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 2/5/21

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed), RFA-AA-21-002, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism. (NIAAA)
Posted on 2/5/21

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed), RFA-AA-21-004, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 2/5/21

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed), RFA-DA-22-004, National Institutes of Health, National Institute on Drug Abuse (NIDA)
Posted on 2/1/21

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed), PAR-21-062, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 1/11/21

HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required), RFA-DA-21-030, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Mental Health; National Center for Complement
Posted on 1/11/21

HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Coordination and Dissemination Center (R24 Clinical Trial Optional), RFA-DA-21-029, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Mental Health; National Center for Complement
Posted on 1/11/21

HEAL Initiative: HEALthy Brain and Child Development Study (Collaborative U01- Clinical Trial Not Allowed), RFA-DA-21-020, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; National Institute of Child Health and Human Development; National Institute
Posted on 1/11/21

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed), PAR-21-062, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases
Posted on 1/12/21

Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional), PAS-21-031, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases
Posted on 1/8/21

Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed), RFA-HG-22-010, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)
Posted on 9/7/20

Multi-Omics for Health and Disease - 'Omics Production Centers (U01 Clinical Trial Not Allowed), RFA-HG-22-009, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)
Posted on 9/7/20

Multi-Omics for Health and Disease - Disease Study Sites (U01 Clinical Trial Optional), RFA-HG-22-008, National Institutes of Health (NIH), National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)
Posted on 9/7/20

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional), PAR-21-092, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/21/20

Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with, RFA-OD-20-023, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases;
Posted on 8/6/20

Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional), RFA-OD-20-022, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Aging; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Diso
Posted on 8/6/20

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed), RFA-OD-20-021, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Nat
Posted on 8/6/20

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed), RFA-OD-20-020, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Nat
Posted on 8/6/20

Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed), RFA-OD-20-019, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of
Posted on 8/6/20

Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed), RFA-OD-20-018, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute of Dental and Craniofacial Research;
Posted on 8/6/20

Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed), RFA-OD-20-017, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculosk
Posted on 8/6/20

Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional), RFA-OD-20-016, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Disea
Posted on 8/6/20

Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed), RFA-OD-20-015, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Drug Abuse; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Library of Medicine; This
Posted on 8/6/20

Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed), RFA-OD-20-014, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Nationa
Posted on 8/6/20

Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional), PAR-20-286, National Institutes of Health; National Institute of Mental Health
Posted on 8/5/20

Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional), PAR-20-279, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 7/27/20

NIDA Core Center of Excellence Grant Program (P30 Clinical Trial Optional), PAR-20-267, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/17/20

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional), PAR-20-249, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/1/20

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional), PAR-20-237, National Institutes of Health; National Institute on Minority Health and Health Disparities; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health
Posted on 6/17/20

Improving Smoking Cessation Interventions among People Living with HIV (R21 Clinical Trial Optional), RFA-CA-20-036, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse
Posted on 6/10/20

Improving Smoking Cessation Interventions among People Living with HIV (R01 Clinical Trial Optional), RFA-CA-20-035, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities
Posted on 6/10/20

Advancing Genomic Medicine Research (Clinical Trial Optional) (R21), RFA-HG-20-037, National Institutes of Health; National Human Genome Research Institute
Posted on 6/4/20

Advancing Genomic Medicine Research (Clinical Trial Optional) (R01), RFA-HG-20-036, National Institutes of Health; National Human Genome Research Institute
Posted on 6/4/20

Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional), RFA-OD-20-013, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Minority Health and Health Disparities; National Institute on Aging; National Eye Institute; National Heart, Lung, and Blood Institute; National Hu
Posted on 6/12/20

NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional), PAR-20-221, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/1/20

Post-Acute Interventions for the Treatment of Anorexia Nervosa (R34 Clinical Trial Required), RFA-MH-20-500, National Institutes of Health; National Institute of Mental Health
Posted on 4/15/20

NIDA Small Research Grant Program (R03 Clinical Trial Required), PA-20-146, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/24/20

Implementing the HIV Service Cascade for Justice-Involved Populations (U01 Clinical Trial Required), RFA-DA-20-028, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/19/20

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required), RFA-OD-20-011, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; U.S. Food and Drug Administration, Center for Tobacco Products
Posted on 2/7/20

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required), RFA-OD-20-010, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 2/7/20

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed), RFA-OD-20-009, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 2/7/20

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed), RFA-OD-20-008, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 2/7/20

Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional), PAR-20-092, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/24/20

Genomic Community Resources (U24 Clinical Trial Not Allowed), PAR-20-100, National Institutes of Health; National Human Genome Research Institute; National Cancer Institute
Posted on 1/23/20

Safety and Feasibility Trials for Rapid-Acting Interventions for Severe Suicide Risk (R01 Clinical Trial Required), RFA-MH-20-345, National Institutes of Health; National Institute of Mental Health
Posted on 11/25/19

Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R01 Clinical Trial Optional), RFA-MH-20-505, National Institutes of Health; National Institute of Mental Health
Posted on 11/25/19

Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R34 Clinical Trial Required), RFA-MH-20-506, National Institutes of Health; National Institute of Mental Health
Posted on 11/25/19

Enhancing Suicide Prevention in Emergency Care via Telehealth (R01 Clinical Trial Optional), RFA-MH-20-226, National Institutes of Health; National Institute of Mental Health
Posted on 11/19/19

Early Psychosis Intervention Network (EPINET): Practice-Based Research to Improve Treatment Outcomes (R01 Clinical Trial Optional), RFA-MH-20-205, National Institutes of Health; National Institute of Mental Health
Posted on 11/18/19

Dysregulation and Proximal Risk for Suicide (R01 Clinical Trial Optional), RFA-MH-20-327, National Institutes of Health; National Institute of Mental Health
Posted on 11/8/19

Dysregulation and Proximal Risk for Suicide (R21 Clinical Trial Optional), RFA-MH-20-326, National Institutes of Health; National Institute of Mental Health
Posted on 11/8/19

Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (Collaborative U01 Clinical Trial Not Allowed), PAR-20-027, National Institutes of Health; National Institute of Mental Health
Posted on 10/20/19

Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (U01 Clinical Trial Not Allowed), PAR-20-026, National Institutes of Health; National Institute of Mental Health
Posted on 10/2/19

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-19-028, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environment
Posted on 9/25/19

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional), PAR-19-368, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute
Posted on 9/9/19

The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required), RFA-DA-20-024, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/4/19

NIDA Program Project Grant Applications (P01 Clinical Trial Optional), PAR-19-345, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/14/19

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-19-327, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/1/19

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01-Clinical Trial Optional), PAR-19-318, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/26/19

Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed), RFA-DA-20-023, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/10/19

Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional), PAR-19-310, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/28/19

PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional), RFA-DA-20-013, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/16/19

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional), PAR-19-259, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/24/19

Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed), RFA-HL-20-014, National Institutes of Health; National Heart, Lung, and Blood Institute; National Center for Advanced of Translational Sciences
Posted on 4/4/19

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis, Informatics and Resource Center (U24 Clinical Trial Not Allowed), RFA-DA-20-003, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 4/3/19

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Linked Research Project Sites (Collaborative U01 Clinical Trial Not Allowed), RFA-DA-20-002, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 4/3/19

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Coordinating Center (U24 Clinical Trial Not Allowed), RFA-DA-20-004, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 4/3/19

Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required), PAR-19-236, National Institutes of Health; National Institute of Mental Health
Posted on 4/2/19

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required), PAR-19-235, National Institutes of Health; National Institute of Mental Health
Posted on 4/2/19

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional), PAR-19-212, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 3/7/19

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), PAR-19-213, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 3/7/19

Centers of Excellence in Genomic Science (RM1 Clinical Trials Optional), PAR-19-204, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health
Posted on 2/28/19

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-19-019, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 2/21/19

Refinement and Testing of Interventions to Sustain ADHD Treatment Effects Across Settings and Developmental Transitions (R34 Clinical Trial Required), RFA-MH-20-100, National Institutes of Health; National Institute of Mental Health
Posted on 2/4/19

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed), PAR-19-162, National Institutes of Health; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities; National Institute of Mental Health; National Cancer Institute; National Center for Complementary and Integrative Health; Nation
Posted on 1/9/19

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed), PAR-19-163, National Institutes of Health; National Institute on Drug Abuse; National Institute of Neurological Disorders and Stroke; National Institute on Minority Health and Health Disparities; National Institute of Mental Health; National Cancer Institute; Eunice
Posted on 1/9/19

Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders (UG1 Clinical Trial Required), RFA-DA-19-018, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/21/18

HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) (UG3/UH3 Clinical Trial Required), RFA-DA-19-035, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute of Child Health and Huma
Posted on 12/10/18

HEAL Initiative: Effectiveness Trials to Optimize, Implement, Scale, and Sustain the Collaborative Care Model for Individuals with Opioid Use Disorders and Mental Health Conditions (U01 Clinical Trial Required), RFA-MH-19-525, National Institutes of Health; National Institute of Mental Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Nursing Research; National Institute on Minority H
Posted on 12/10/18

HEAL Initiative: Coordinating Center to Support NIDA Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) Initiative (U24 Clinical Trial Not Allowed), RFA-DA-19-034, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute of Child Health and Huma
Posted on 12/10/18

HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Clinical Research Centers (UG1 Clinical Trial Optional), RFA-DA-19-025, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 12/10/18

HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Coordination and Translation Center (U2C Clinical Trial Optional), RFA-DA-19-024, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 12/10/18

HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Methodology and Advanced Analytics Resource Center (U2C Clinical Trial Not Allowed), RFA-DA-19-023, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 12/10/18

Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed), PA-19-043, National Institutes of Health; National Human Genome Research Institute
Posted on 10/31/18

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional), PAR-19-064, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 11/9/18

HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis (Data Coordinating Center) (UM1 - Clinical Trials Not Allowed), RFA-DA-19-017, National Institutes of Health; Substance Abuse and Mental Health Services Administration; National Institute on Drug Abuse
Posted on 9/19/18

HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional), PAS-18-915, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/10/18

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional), PA-18-916, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/10/18

Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional), PAR-18-918, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/10/18

Responding to Opioid Use Disorders (OUD) in Tribal Communities in the Context of SAMHSA and CDC Funding (R61/R33 - Clinical Trials Optional), RFA-DA-19-013, National Institutes of Health; National Institute on Drug Abuse; Office of Behavioral and Social Sciences Research; Tribal Health Research Office
Posted on 9/18/18

HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis (Research Sites) (UM1 - Clinical Trial Required), RFA-DA-19-016, National Institutes of Health; Substance Abuse and Mental Health Services Administration; National Institute on Drug Abuse
Posted on 9/19/18

The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Optional), RFA-DA-19-008, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/26/18

Dysregulation and Proximal Risk for Suicide FOA (R01 Clinical Trial Optional), RFA-MH-19-211, National Institutes of Health; National Institute of Mental Health
Posted on 10/3/18

Dysregulation and Proximal Risk for Suicide (R21 Clinical Trial Optional), RFA-MH-19-210, National Institutes of Health; National Institute of Mental Health
Posted on 10/3/18

Improving Smoking Cessation Interventions among People Living with HIV (R21 Clinical Trial Optional), RFA-CA-18-028, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse
Posted on 8/24/18

Improving Smoking Cessation Interventions among People Living with HIV (R01 Clinical Trial Optional), RFA-CA-18-027, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities
Posted on 8/24/18

Early Psychosis Intervention Network (EPINET): Data Coordinating Center (U24 Clinical Trial Not Allowed), RFA-MH-19-151, National Institutes of Health; National Institute of Mental Health
Posted on 7/30/18

Early Psychosis Intervention Network (EPINET): Practice-Based Research to Improve Treatment Outcomes (R01 Clinical Trial Optional), RFA-MH-19-150, National Institutes of Health; National Institute of Mental Health
Posted on 7/30/18

Novel Approaches for Relating Genetic Variation to Function and Disease (R21 Clinical Trial Not Allowed), PA-18-867, National Institutes of Health; National Human Genome Research Institute
Posted on 7/23/18

Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed), PA-18-868, National Institutes of Health; National Human Genome Research Institute
Posted on 7/23/18

Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (Collaborative U01 Clinical Trial Not Allowed), RFA-MH-19-201, National Institutes of Health; National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development
Posted on 6/7/18

Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (U01 Clinical Trial Not Allowed), RFA-MH-19-200, National Institutes of Health; National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development
Posted on 6/7/18

Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed), PAR-18-789, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/16/18

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed), RFA-OD-18-005, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; National Institute of Environmental Health Sciences
Posted on 5/15/18

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required), RFA-OD-18-006, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse
Posted on 5/15/18

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required), RFA-OD-18-008, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse
Posted on 5/15/18

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed), RFA-OD-18-007, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; National Institute of Environmental Health Sciences
Posted on 5/15/18

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 - Clinical Trial Optional), PA-18-780, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/10/18

International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional), PA-18-773, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/9/18

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional), PA-18-775, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/9/18

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional), PAR-18-746, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/6/18

Investigator-Initiated Genomic Medicine Research (R01 Clinical Trial Optional), PAR-18-735, National Institutes of Health; National Human Genome Research Institute
Posted on 4/2/18

Investigator-Initiated Genomic Medicine Research (R21 Clinical Trial Optional), PAR-18-736, National Institutes of Health; National Human Genome Research Institute
Posted on 4/2/18

Coordinating Center to Support NIDA Rural Opioid HIV and Comorbidity Initiative (U24 - Clinical Trial Not Allowed), RFA-DA-19-004, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/20/18

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01, Clinical Trial Optional), RFA-DA-18-022, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/14/18

Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment (R61/R33 Clinical Trial Required), RFA-DA-19-005, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/5/18

NIDA Small Research Grant Program (R03 Clinical Trial Required), PA-18-634, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/6/18

NIDA Small Research Grant Program (R03 Clinical Trial Required), PA-18-626, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/2/18

NIDA Academic Research Enhancement Award (R15, Clinical Trials Required), PA-18-627, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/2/18

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01, Clinical Trial Optional), PA-18-569, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 1/11/18

International Research Collaboration on Drug Abuse and Addiction Research (R01, Clinical Trial Optional), PA-18-568, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/18

Improving Implementation of Seek, Test, Treat and Retain Strategies among People Who Inject Drugs in Low to Middle Income Countries (R01-Clinical Trial Required), RFA-DA-18-017, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/22/17

Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01- Clinical Trial Not Allowed), RFA-DA-18-023, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/21/17

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional), PAR-18-527, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/18/17

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 ), PAR-18-510, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/18/17

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 Clinical Trial Optional ), PAR-18-509, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/18/17

Device-Based Treatments for Substance Use Disorders (UG3/UH3) (Clinical Trial Optional), PAR-18-494, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 12/15/17

Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional), RFA-DA-19-002, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/14/17

Pilot Effectiveness Trials for Post-Acute Interventions and Serivces to Optimize Longer-Term Outcomes (R34-Clinical Trials Required), PAR-18-431, National Institutes of Health; National Institute of Mental Health
Posted on 12/6/17

Effectiveness Trials for Post-Acute Interventions and Services and Services to Optimize Longer-Term Outcomes (R01-Clinical Trials Required), PAR-18-430, National Institutes of Health; National Institute of Mental Health
Posted on 12/1/17

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3, Clinical Trial Optional), RFA-DA-18-020, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/6/17

NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional), RFA-DA-18-019, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/6/17

NIDA Core Center of Excellence Grant Program (P30 Clinical Trial Optional), PAR-18-225, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/30/17

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional), PAR-18-224, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/30/17

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional), PAR-18-226, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/30/17

NIDA Program Project Grant Applications (P01, Clinical Trial Optional), PAR-18-425, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/29/17

Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3 Clinical Trial Optional), PAR-18-221, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/29/17

Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required), PAR-18-233, National Institutes of Health; National Institute of Mental Health
Posted on 11/21/17

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required), PAR-18-232, National Institutes of Health; National Institute of Mental Health
Posted on 11/21/17

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-18-219, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/21/17

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01 Clinical Trial Optional), PAR-18-218, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/21/17

Ancillary Studies to Identify Behavioral and/or Psychological Phenotypes Contributing to Obesity (R01 Clinical Trial Optional), PAR-18-105, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; Office of Behavioral and Social Sciences Research
Posted on 11/21/17

Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional), RFA-OD-18-001, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 11/20/17

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-18-002, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 11/20/17

Tobacco Regulatory Science (R21 Clinical Trial Optional), RFA-OD-18-003, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 11/20/17

Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional), PAR-18-082, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/17/17

Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional), PAR-18-081, National Institutes of Health; National Institute on Drug Abuse; National Institute of Biomedical Imaging and Bioengineering
Posted on 11/17/17

Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33), RFA-AT-18-002, National Institutes of Health; National Center for Complementary and Integrative Health
Posted on 11/16/17

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional), PA-18-072, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/15/17

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 Clinical Trial Optional), PA-18-071, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/15/17

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21 Clinical Trial Optional), PA-18-070, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 11/15/17

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03 Clinical Trial Optional), PA-18-069, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 11/15/17

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34 Clinical Trial Optional), PA-18-068, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 11/15/17

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional), PA-18-067, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 11/15/17

International Research Collaboration on Drug Abuse and Addiction Research (R21 Clinical Trial Optional), PA-18-066, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/15/17

International Research Collaboration on Drug Abuse and Addiction Research (R03 Clinical Trial Optional), PA-18-065, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/15/17

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01- Clinical Trial Required), RFA-MH-18-707, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required), RFA-MH-18-706, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33- Clinical Trial Required), RFA-MH-18-705, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33- Clinical Trial Required), RFA-MH-18-704, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Early Stage Testing of Pharmacologic or Device -based Interventions for the Treatment of Mental Health Disorders (R33- Clinical Trial Required), RFA-MH-18-703, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33-Clinical Trial Required), RFA-MH-18-702, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01- Clinical Trial Required), RFA-MH-18-701, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01-Clinical Trial Required), RFA-MH-18-700, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional), PAR-18-064, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute
Posted on 11/8/17

Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional), PA-18-078, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/3/17

Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional), PA-18-060, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/3/17

Prescription Drug Abuse (R21 Clinical Trial Optional), PA-18-076, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/2/17

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21 Clinical Trial Optional), PA-18-075, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/2/17

Behavioral and Integrative Treatment Development Program (R03 Clinical Trial Optional), PA-18-074, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 11/2/17

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), PA-18-073, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 11/2/17

Prescription Drug Abuse (R01 Clinical Trial Optional), PA-18-058, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/2/17

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01 Clinical Trial Optional), PA-18-056, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/2/17

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional), PA-18-055, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 11/2/17

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional), PAR-18-062, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism
Posted on 11/1/17

The Application of Big Data Analytics to Drug Abuse Research (R01 Clinical Trial Optional), PA-18-057, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/1/17

Pharmacogenomics of Anti-retroviral Therapy in People Who Inject Drugs (R01), RFA-DA-18-014, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/3/17

Tobacco Regulatory Science Small Grant Program for New Investigators (R03), RFA-OD-17-012, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 7/20/17

Tobacco Regulatory Science (R21), RFA-OD-17-014, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 7/20/17

Tobacco Regulatory Science (R01), RFA-OD-17-013, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 7/20/17

The NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL) (U24), RFA-HG-17-011, National Institutes of Health; National Human Genome Research Institute
Posted on 7/17/17

Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse (U01), RFA-DA-18-011, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/14/17

HIV/HCV Co-Infections in Substance Abusers (R01), PAS-17-311, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/13/17

Addressing Suicide Research Gaps: Understanding Mortality Outcomes (R01), RFA-MH-18-410, National Institutes of Health; National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute on Drug Abuse; National Institue on Minority Health and Health Disparities
Posted on 5/25/17

Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33), RFA-AT-18-001, National Institutes of Health; National Center for Complementary and Integrative Health
Posted on 5/17/17

Tobacco Regulatory Science (R21), RFA-OD-17-009, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 5/10/17

Tobacco Regulatory Science Small Grant Program for New Investigators (R03), RFA-OD-17-008, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 5/10/17

Tobacco Regulatory Science (R01), RFA-OD-17-007, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 5/10/17

Genomic Community Resources (U24), PAR-17-273, National Institutes of Health; National Human Genome Research Institute; National Cancer Institute
Posted on 5/8/17

Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01), PAR-17-272, National Institutes of Health; National Institute of Mental Health
Posted on 5/4/17

Pilot Effectivness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34), PAR-17-271, National Institutes of Health; National Institute of Mental Health
Posted on 5/4/17

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (Collaborative R01), PAR-17-252, National Institutes of Health; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism
Posted on 4/11/17

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (R01), PAR-17-253, National Institutes of Health; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism
Posted on 4/11/17

Expanding Medication Assisted Treatment for Opioid Use Disorders in the Context of the SAMHSA Opioid STR Grants (R21/R33), RFA-DA-18-005, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/10/17

Extracellular Vesicles and Substance Use Disorders (R21), PAR-17-242, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/4/17

Extracellular Vesicles and Substance Use Disorders (R01), PAR-17-250, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/4/17

Center for Coordination of Analytics, Science, Enhancement , and Logistics (CASEL) in Tobacco Regulatory Science (U54), RFA-OD-17-002, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Institute on Drug Abuse; U.S. Food and Drug Administration, Center for Tobacco P
Posted on 3/13/17

Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54), RFA-OD-17-003, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 3/13/17

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3), RFA-DA-18-003, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/8/17

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (Collaborative U01), PAR-17-176, National Institutes of Health; National Institute of Mental Health
Posted on 2/27/17

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (U01), PAR-17-179, National Institutes of Health; National Institute of Mental Health
Posted on 2/27/17

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R21), PA-17-157, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/8/17

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R01), PA-17-155, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/8/17

Basic Mechanisms of Brain Development Mediating Substance Use and Dependence (R01), PA-17-119, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 1/10/17

Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01), PA-17-120, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/10/17

Neuroscience Research on Drug Abuse (R21), PA-17-112, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/17

Neuroscience Research on Drug Abuse (R01), PA-17-111, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/17

NIDA Core Center of Excellence Grant Program (P30), PAR-17-121, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/17

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01), RFA-MH-17-614, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34), RFA-MH-17-612, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01), RFA-MH-17-610, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33), RFA-MH-17-602, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01), RFA-MH-17-608, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33), RFA-MH-17-604, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33), RFA-MH-17-606, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33), RFA-MH-17-600, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

NIH-DoD-VA Pain Management Collaboratory - Pragmatic Clinical Trials Demonstration Projects (UG3/UH3), RFA-AT-17-001, National Institutes of Health; Department of Defense; Department of Veterans Affairs; National Center for Complementary and Integrative Health; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health a
Posted on 12/12/16

Hepatitis C Virus (HCV) Advanced Molecular Detection in Support of Systems for Prevention, Treatment and Control of HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States (U24), RFA-DA-17-023, National Institutes of Health; Centers for Disease Control and Prevention; National Institute on Drug Abuse; National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention
Posted on 10/6/16

HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (UG3/UH3), RFA-DA-17-014, National Institutes of Health; Centers for Disease Control and Prevention; Substance Abuse and Mental Health Services Administration; Appalachian Regional Commission; National Institute on Drug Abuse; National Center for HIV/AIDS, Viral Hepatitis, STD and
Posted on 10/6/16

Drug Abuse Dissertation Research (R36), PA-16-443, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/22/16

Centers of Excellence in Genomic Science (CEGS) (RM1), PAR-16-436, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health
Posted on 9/19/16

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01), PAR-16-430, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/8/16

Grand Opportunity in Medications Development for Substance-Use Disorders (U01), PAR-16-431, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/8/16

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24), RFA-DA-17-019, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/7/16

NIDA Program Project Grant Applications (P01), PAR-16-393, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/5/16

Chemistry Science Track Award for Rapid Transition (C/START) (R03), PAR-16-383, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/1/16

Chemical Discovery (CHEM) Award (R21/R33), PAR-16-384, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/1/16

Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01), RFA-DA-17-013, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/28/16

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1), PAR-16-357, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/7/16

Ancillary Studies to Identify Behavioral and/or Psychological Phenotypes Contributing to Obesity (R01), PAR-16-304, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; Office of Behavioral and Social Sciences Research
Posted on 6/1/16

Reducing the Duration of Untreated Psychosis in the United States (R01), PAR-16-265, National Institutes of Health; National Institute of Mental Health
Posted on 5/17/16

Reducing the Duration of Untreated Psychosis in the United States (R34), PAR-16-264, National Institutes of Health; National Institute of Mental Health
Posted on 5/17/16

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01), PAR-16-234, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/10/16

Prescription Drug Abuse (R21), PA-16-232, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/10/16

Prescription Drug Abuse (R01), PA-16-233, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/10/16

Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research (R41/R42), RFA-DA-17-008, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/22/16

Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research (R43/R44), RFA-DA-17-009, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/22/16

Role of Astrocytes and Astrocytic Networks in Drug Abuse (R21), PA-16-145, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/22/16

Role of Astrocytes and Astrocytic Networks in Drug Abuse (R01), PA-16-144, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/22/16

The Application of Big Data Analytics to Drug Abuse Research (R01), PA-16-119, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/9/16

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3), RFA-DA-17-015, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/9/16

Services Planning Research in the Appalachian Region to Address Adverse Health Consequences Associated with Increased Opioid Injection Drug Use (R03), RFA-DA-16-015, National Institutes of Health; Appalachian Regional Commission; National Institute on Drug Abuse
Posted on 2/19/16

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21), PA-16-075, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/8/16

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01), PA-16-076, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/8/16

Behavioral and Integrative Treatment Development Program (R03), PA-16-074, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 1/8/16

Behavioral and Integrative Treatment Development Program (R01), PA-16-072, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 1/8/16

Behavioral and Integrative Treatment Development Program (R34), PA-16-073, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 1/8/16

Behavioral Science Track Award for Rapid Transition (B/Start)(R03), PAR-16-071, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/8/16

Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01), RFA-DA-16-012, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/14/15

Systems Biology Approaches in HIV/AIDS and Substance Use (R01), RFA-DA-16-013, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/10/15

Mechanism for Time-Sensitive Drug Abuse Research (R21), PAR-16-055, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/10/15

Seek, Test, Treat and Retain For Youth and Young Adults Living with or at High Risk for Acquiring HIV (R01), RFA-DA-16-010, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/8/15

Effects of Drugs of Abuse on Latent HIV Reservoirs in the CNS (R01), RFA-DA-16-014, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/8/15

Integration of Infectious Diseases and Substance Abuse Intervention Services for Individuals Living with HIV (R01), RFA-DA-16-011, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/7/15

Environmental Influences on Child Health Outcomes: Patient Reported Outcomes Research Resource Center Core (ECHO PRO Core) (U24), RFA-OD-16-003, National Institutes of Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Nationa
Posted on 12/7/15

Environmental Influences on Child Health Outcomes (ECHO) Pediatric Cohorts (UG3/UH3), RFA-OD-16-004, National Institutes of Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Nationa
Posted on 12/7/15

NIDA Research Center of Excellence Grant Program (P50), PAR-16-009, National Institutes of Health; National Institute on Drug Abuse
Posted on 10/21/15

Major Opportunities for Research in Epidemiology of Alzheimer's Disease and Cognitive Resilience (R01), PAR-15-356, National Institutes of Health; National Institute on Aging
Posted on 9/24/15

AIDS-Science Track Award for Research Transition (R03), PA-15-290, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/9/15

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3), RFA-DA-16-008, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/21/15

Imaging - Science Track Award for Research Transition (I/START) (R03), PAR-15-326, National Institutes of Health; National Institute on Drug Abuse; National Institute of Biomedical Imaging and Bioengineering
Posted on 8/7/15

Tools for Monitoring and Manipulating Modified RNAs in the Nervous System (R43/R44), RFA-DA-16-005, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/21/15

Tools for Monitoring and Manipulating Modified RNAs in the Nervous System (R41/R42), RFA-DA-16-006, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/21/15

Data Coordinating Center for Sickle Cell Disease Implementation Consortium (SCDIC): Using Implementation Science to Optimize Care of Adolescents and Adults with Sickle Cell Disease (U24), RFA-HL-16-011, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Minority Health and Health Disparities
Posted on 7/15/15

Extracellular Vesicles and Substance Abuse (R21), PAR-15-284, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/19/15

Extracellular Vesicles and Substance Abuse (R01), PAR-15-283, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/19/15

Longitudinal Assessment of Post -traumatic Syndromes (U01), RFA-MH-16-500, National Institutes of Health; National Institute of Mental Health
Posted on 6/12/15

Tools and Services for Designing Methodologically Rigorous Animal Studies (R41/R42), RFA-DA-16-002, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/4/15

Tools and Services for Designing Methodologically Rigorous Animal Studies (R43/R44), RFA-DA-16-003, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/4/15

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34), PA-15-268, National Institutes of Health; National Institute on Drug Abuse; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health
Posted on 5/28/15

Harnessing Genome Editing Technologies to Functionally Validate Genetic Variants in Substance Use Disorders (R21/R33), RFA-DA-16-004, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/27/15

Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3), PAR-15-267, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/26/15

Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R61/R33), RFA-MH-16-406, National Institutes of Health; National Institute of Mental Health
Posted on 5/22/15

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03), PA-15-252, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/8/15

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34), PA-15-250, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/8/15

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01), PA-15-251, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/8/15

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34), PA-15-250, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/8/15

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21), PA-15-253, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/8/15

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34), PA-15-177, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 4/7/15

Clinical Trials to Test the Effectiveness of Treatment, Preventive and Services Interventions (Collaborative R01), RFA-MH-16-415, National Institutes of Health; National Institute of Mental Health
Posted on 3/30/15

Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R33), RFA-MH-16-400, National Institutes of Health; National Institute of Mental Health
Posted on 3/30/15

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01), RFA-MH-16-420, National Institutes of Health; National Institute of Mental Health
Posted on 3/30/15

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01), RFA-MH-16-425, National Institutes of Health; National Institute of Mental Health
Posted on 3/30/15

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34), RFA-MH-16-410, National Institutes of Health; National Institute of Mental Health
Posted on 3/30/15

International Research Collaboration on Drug Abuse and Addiction Research (R21), PA-15-143, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/17/15

International Research Collaboration on Drug Abuse and Addiction Research (R01), PA-15-142, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/17/15

International Research Collaboration on Drug Abuse and Addiction Research (R03), PA-15-141, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/17/15

Identification of Genetic and Genomic Variants by Next-Gen in Sequencing Non-human Animal Models (U01), PAR-15-120, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/13/15

NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12), PAR-15-119, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/11/15

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01), RFA-DA-16-001, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/10/15

Gene-Environment Interplay in Substance Use Disorders (R21), PA-15-112, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 2/5/15

Gene-Environment Interplay in Substance Use Disorders (R03), PA-15-111, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 2/5/15

Gene-Environment Interplay in Substance Use Disorders (R01), PA-15-110, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 2/5/15

Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis and Informatics Center (U24), RFA-DA-15-016, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 2/4/15

Adolescent Brain Cognitive Development (ABCD) Study - Research Project Sites (U01), RFA-DA-15-015, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 2/4/15

Adolescent Brain Cognitive Development (ABCD) Study - Coordinating Center (U24), RFA-DA-15-014, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 2/4/15

Reductions in Illicit Drug Use and Functional Outcomes (R21/R33), PA-15-099, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/23/15

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3), RFA-DA-15-017, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/16/15

Drug Abuse Prevention Intervention Research (R21), PA-15-080, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/15

Drug Abuse Prevention Intervention Research (R03), PA-15-081, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/15

Drug Abuse Prevention Intervention Research (R01), PA-15-082, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/15

Identification of Genetic and Genomic Variants by Next-Gen in Sequencing Non-human Animal Models (U01), PAR-15-120, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/13/15

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01), RFA-DA-16-001, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/10/15

Gene-Environment Interplay in Substance Use Disorders (R21), PA-15-112, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 2/5/15

Gene-Environment Interplay in Substance Use Disorders (R03), PA-15-111, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 2/5/15

Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis and Informatics Center (U24), RFA-DA-15-016, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 2/4/15

Reductions in Illicit Drug Use and Functional Outcomes (R21/R33), PA-15-099, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/23/15

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3), RFA-DA-15-017, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/16/15

Drug Abuse Prevention Intervention Research (R01), PA-15-082, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/15

Children's Health Exposure Analysis Resource (CHEAR): Coordinating Center (U24), RFA-ES-15-011, National Institutes of Health; National Institute of Environmental Health Sciences
Posted on 2/26/15

Epidemiology of Drug Abuse (R21), PA-15-001, National Institutes of Health; National Institute on Drug Abuse
Posted on 10/3/14

Epidemiology of Drug Abuse (R03), PA-15-002, National Institutes of Health; National Institute on Drug Abuse
Posted on 10/3/14

Epidemiology of Drug Abuse (R01), PA-15-003, National Institutes of Health; National Institute on Drug Abuse
Posted on 10/3/14

Enhancing Cross-National Research within the Health and Retirement Study Family of Studies (R01), RFA-AG-15-015, National Institutes of Health; National Institute on Aging
Posted on 7/30/14

Interventions for Youth who Misuse/Abuse Prescription Stimulant Medications in High School and/or College-Attending Youth (U01), RFA-DA-15-010, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/22/14

Extracellular Vesicles in HIV/AIDS and Substance Abuse (R21), RFA-DA-15-012, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/16/14

Extracellular Vesicles in HIV/AIDS and Substance Abuse (R01), RFA-DA-15-011, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/16/14

The National Drug Abuse Treatment Clinical Trials Network (UG1), RFA-DA-15-008, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/3/14

Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R33), PAR-14-231, National Institutes of Health; National Institute on Drug Abuse; National Institute of Mental Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/19/14

Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R21/R33), PAR-14-230, National Institutes of Health; National Institute on Drug Abuse; National Institute of Mental Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/19/14

Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01), PAR-14-225, National Institutes of Health; National Institute on Drug Abuse; National Center for Complementary and Integrative Health; National Cancer Institute
Posted on 5/15/14

Long-Term Retention in Care for U.S. Substance Using Populations (R01), PA-14-224, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/15/14

Long-Term Retention in Care for U.S. Substance Using Populations (R21), PA-14-223, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/15/14

Long-Term Retention in Care for U.S. Substance Using Populations (R34), PA-14-222, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/15/14

Centers of Excellence in Genomic Science (CEGS) (RM1), PAR-14-195, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health
Posted on 4/28/14

Epidemiology and Prevention in Alcohol Research (R01), PA-14-190, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
Posted on 4/24/14

Epidemiology and Prevention in Alcohol Research (R03), PA-14-189, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
Posted on 4/24/14

Epidemiology and Prevention in Alcohol Research (R21), PA-14-188, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
Posted on 4/24/14

Genomic Resource Grants for Community Resource Projects (U41), PAR-14-191, National Institutes of Health; National Cancer Institute; National Human Genome Research Institute
Posted on 4/24/14

NIDA Core Center of Excellence Grant Program (P30), PAR-14-186, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/23/14

Effects of Cannabis Use and Cannabinoids on the Developing Brain (R01), PA-14-163, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/26/14

Effects of Cannabis Use and Cannabinoids on the Developing Brain (R21), PA-14-162, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/26/14

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01), PA-14-137, National Institutes of Health; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases
Posted on 3/3/14

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21), PA-14-136, National Institutes of Health; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases
Posted on 3/3/14

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34), PA-14-135, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/3/14

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01), PAR-14-106, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/20/14

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21), PAR-14-105, National Institutes of Health; National ?Institute on Drug Abuse
Posted on 2/20/14

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03), PAR-14-104, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/20/14

NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1), RFA-DA-15-004, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/13/14

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01), RFA-DA-15-005, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/5/14

Neuroimmune Signaling in Substance Use Disorders (R01), PA-14-084, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/4/14

Neuroimmune Signaling and Function in Substance Use Disorders (R21), PA-14-083, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/4/14

Medications Development Centers of Excellence Cooperative Program (U54), RFA-DA-15-003, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/31/14

Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R01), PA-14-061, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 1/7/14

Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R21), PA-14-062, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 1/7/14

Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R03), PA-14-063, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 1/7/14

Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R21), PA-14-036, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 12/12/13

Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03), PA-14-037, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 12/12/13

Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01), PA-14-038, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 12/12/13

Basic Mechanisms of Brain Development for Substance Use and Dependence (R01), PA-14-026, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 12/11/13

Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01), PA-14-025, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/10/13

Public Health Impact of the Changing Policy/Legal Environment for Marijuana (R01), PAS-14-020, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/6/13

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Abuse (R21), PA-14-013, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/5/13

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Abuse (R01), PA-14-014, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/5/13

Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM) (R21/R33), PAR-13-350, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/11/13

Neuroscience Research on Drug Abuse (R03), PA-13-336, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/26/13

Neuroscience Research on Drug Abuse (R21), PA-13-337, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/26/13

Neuroscience Research on Drug Abuse (R01), PA-13-338, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/19/13

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01), PAR-13-334, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/19/13

Administrative Supplements to Promote Collaborative Research on Addiction at NIH (CRAN): Comorbidity-Related Research (Admin Supp), PA-13-275, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism
Posted on 7/15/13

Grand Opportunity in Medications Development for Substance-Use Disorders (U01), PAR-13-270, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/11/13

Seek, Test, Treat, and Retain Data Harmonization Coordinating Center (U01), RFA-DA-14-007, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/31/13

FY14 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1), RFA-DA-14-008, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/30/13

NIDA Research Center of Excellence Grant Program (P50), PAR-13-222, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/6/13

Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R01), RFA-DA-14-005, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/3/13

Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R21), RFA-DA-14-006, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/3/13

Medications Development Centers of Excellence Cooperative Program (U54), RFA-DA-14-004, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/26/13

Centers of Excellence in Genomic Science (CEGS) (P50), PAR-13-198, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health
Posted on 4/12/13

Drug Abuse Dissertation Research (R36), PAR-13-182, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/5/13

Revision Applications to Promote Collaborative Research on Addiction at NIH (CRAN): Comorbidity-Related Research (R01), RFA-DA-14-014, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism
Posted on 7/15/13

NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12), PAR-13-163, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/28/13

Prevention and Health Promotion Interventions to Prevent Alcohol and Other Drug Abuse and Associated Physical and Psychological Health Problems in U.S. Military Personnel, Veterans and their Families (R01), RFA-DA-13-012, National Institutes of Health; The Department of Defense; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of the Assistant Secretary of Defense for Health Affairs
Posted on 1/30/13

Prevention and Health Promotion Interventions to Prevent Alcohol and Other Drug Abuse and Associated Physical and Psychological Health Problems in U.S. Military Personnel, Veterans and their Families (R34), RFA-DA-13-013, National Institutes of Health; The Department of Defense; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Center for Complementary and Alternative Medicine; Office of the Assistant Secretary of Defense for He
Posted on 1/30/13

Behavioral & Integrative Treatment Development Program (R01), PA-13-077, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Center for Complementary and Integrative Health
Posted on 1/9/13

Behavioral & Integrative Treatment Development Program (R34), PA-13-078, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 1/9/13

Behavioral & Integrative Treatment Development Program (R03), PA-13-079, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 1/9/13

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01), PAR-13-080, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute
Posted on 1/9/13

Prescription Drug Abuse (R01), PA-13-015, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/2/12

Prescription Drug Abuse(R21), PA-13-016, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/2/12

Drug Abuse Aspects of HIV/AIDS (R01), PA-12-293, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/25/12

Drug Abuse Aspects of HIV/AIDS (R03), PA-12-294, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/25/12

Drug Abuse Aspects of HIV/AIDS (R21), PA-12-295, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/25/12

HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21), PA-12-280, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/10/12

HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R01), PA-12-281, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/10/12

Human Heredity and Health in Africa (H3Africa): Collaborative Centers (U54), RFA-RM-12-006, National Institutes of Health; This Funding Opportunity Announcement; Division of Program Coordination, Planning and Strategic Initiatives; Office of Strategic Coordination; National Human Genome Research Institute; Eunice Kennedy Shriver National Institu
Posted on 8/22/12

Human Heredity and Health in Africa (H3Africa): H3Africa Research Grants (U01), RFA-RM-12-007, National Institutes of Health; This Funding Opportunity Announcement; Division of Program Coordination, Planning and Strategic Initiatives; Office of Strategic Coordination; National Human Genome Research Institute; Eunice Kennedy Shriver National Institu
Posted on 8/22/12

Behavioral Science Track Award for Rapid Transition (B/START) (R03), PAR-12-251, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/26/12

Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21), PAR-12-238, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/16/12

Human Heredity and Health in Africa (H3Africa): H3Africa Research Grants (U01), PAR-12-239, National Institutes of Health; This Funding Opportunity Announcement; Division of Program Coordination, Planning and Strategic Initiatives; Office of Strategic Coordination; National Human Genome Research Institute; Eunice Kennedy Shriver National Institu
Posted on 8/22/12

Cohort Studies of HIV/AIDS and Substance Use (U01), PAR-12-222, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/6/12

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34), PA-12-231, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/6/12

Research Education Grants for Statistical and Computational Training in the Genetics of Addiction (R25), PAR-12-199, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/8/12

Small Grants for Behavioral Research in Cancer Control (R03), PAR-12-035, National Institutes of Health; National Cancer Institute
Posted on 12/22/11

Gene-Environment Interplay in Substance Use Disorders (R21), PA-11-236, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 7/19/11

Gene-Environment Interplay in Substance Use Disorders (R03), PA-11-237, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 7/19/11

Gene-Environment Interplay in Substance Use Disorders (R01), PA-11-235, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 7/19/11

Personalized Genomics for Symptom Management: Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R01), RFA-NR-11-003, National Institutes of Health; National Institute of Nursing Research
Posted on 1/11/11

Personalized Genomics for Symptom Management: Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R21), RFA-NR-11-004, National Institutes of Health; National Institute of Nursing Research
Posted on 1/11/11

The Electronic Medical Records and Genomics (eMERGE) Network, Phase II Coordinating Center (U01), RFA-HG-10-010, National Institutes of Health; National Human Genome Research Institute; The Electronic Medical Records and Genomics
Posted on 7/15/10

Pharmacogenomics Research Network (U01/U19), RFA-GM-10-001, National Institutes of Health; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institute on Drug Abuse; National Institute on Mental Health; National Institute of Child Health
Posted on 1/30/09

Genome-wide Association Studies of Treatment Response in Randomized Clinical Trials-Study Investigators (U01), RFA-HG-08-004, National Institutes of Health; National Human Genome Research Institute
Posted on 8/19/08

Genome-wide Association Studies of Treatment Response in Randomized Clinical Trials - Coordinating Center (U01), RFA-HG-08-005, National Institutes of Health; National Human Genome Research Institute
Posted on 8/19/08

2025

Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional), RFA-OD-25-008, National Institutes of Health (NIH), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Drug Abuse (NIDA)
Posted on 6/24/25

Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional), PAR-25-383, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Mental Health (NIMH), Office of Behavioral and Social Sciences Research (OBSSR)
Posted on 6/17/25

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional), PAR-25-379, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR), National Library of Medicine (NLM), Office of Behavioral and Social Sciences Research (OBSSR), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH), Tribal Health Research Office (THRO)
Posted on 1/21/25

Leadership and Coordination Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed), RFA-HL-26-011, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR), Office of Research on Women's Health (ORWH)
Posted on 1/16/25

Limited Competition: Data Analysis and Sharing Center (DASC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed), RFA-HL-26-010, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR), Office of Research on Women's Health (ORWH)
Posted on 1/16/25

Limited Competition: Clinical Research Sites (CRS) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trial Not Allowed), RFA-HL-26-009, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR), Office of Research on Women's Health (ORWH)
Posted on 1/16/25

Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional), PAR-25-371, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI), National Eye Institute (NEI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Neurological Disorders and Stroke (NINDS), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women's Health (ORWH), Tribal Health Research Office (THRO)
Posted on 1/13/25

Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional), PAR-25-370, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), FIC, National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), Office of Behavioral and Social Sciences Research (OBSSR), Office of Data Science Strategy (ODSS), Office of Research on Women's Health (ORWH), Tribal Health Research Office (THRO)
Posted on 1/13/25

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional), PAR-25-369, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), FIC, National Cancer Institute (NCI), NEI, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women's Health (ORWH), Tribal Health Research Office (THRO)
Posted on 1/13/25

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed), PAR-25-068, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Posted on 1/8/25

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-25-328, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Posted on 1/3/25

2024

Advancing Vision Health Equity through Multi-level Interventions and Community-Engaged Research (R01 - Clinical Trial Optional), RFA-EY-25-002, National Eye Institute (NEI), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 12/30/24

D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional), PAS-25-236, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Posted on 12/16/24

Risk and Protective Factors of Family Health and Family Level Interventions (R01 Clinical Trial Optional), PAR-25-317, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Nursing Research (NINR), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH), Sexual and Gender Minority Research Office (SGMRO), Tribal Health Research Office (THRO)
Posted on 12/13/24

Limited Competition: Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial Optional), RFA-MD-24-011, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH)
Posted on 12/9/24

Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional), PAR-24-330, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), Office of Behavioral and Social Sciences Research (OBSSR)
Posted on 12/6/24

Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed), RFA-DA-26-055, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Posted on 12/5/24

Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed), RFA-DA-26-056, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Posted on 12/5/24

High-Priority Research in Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-25-001, Office of Disease Prevention (ODP), National Institutes of Health (NIH), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Drug Abuse (NIDA)
Posted on 12/5/24

Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional), PAR-25-299, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 12/5/24

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional), PAR-25-242, Fogarty International Center (FIC), National Institutes of Health (NIH), National Cancer Institute (NCI), National Eye Institute (NEI), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Mental Health (NIMH), Office of Dietary Supplements (ODS), Office of Research on Women's Health (ORWH)
Posted on 12/4/24

Accelerating Solutions to Improve Access and Quality of Empirically-Supported Practices for Youth Mental Health (R01 Clinical Trial Optional), PAR-25-310, National Institute of Mental Health (NIMH), National Institutes of Health (NIH)
Posted on 12/3/24

Research to Address Systemic and Structural Barriers and Facilitators to Improve the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum for People Who Use Substances (R01 Clinical Trials Required), RFA-DA-26-003, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), Office of AIDS Research (OAR), Office of Research on Women's Health (ORWH)
Posted on 12/2/24

Translational Neural Devices (R61/R33 - Clinical Trial Optional), PAR-25-053, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Posted on 10/29/24

Environmental Health Disparities Centers (P50) Clinical Trial Optional, RFA-MD-24-010, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), Environmental Influences on Child Health Outcomes (ECHO), National Cancer Institute (NCI), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), National Institute of Nursing Research (NINR)
Posted on 10/21/24

HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional), RFA-NS-25-020, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA)
Posted on 10/8/24

Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional), PAR-24-273, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), National Institute of Nursing Research (NINR), Office of Disease Prevention (ODP), National Cancer Institute (NCI), National Institute on Aging (NIA)
Posted on 8/27/24

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional), RFA-DA-25-024, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)
Posted on 8/2/24

Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations II (U01 Clinical Trial Not Allowed), PAR-24-240, National Institute of Mental Health (NIMH), National Institutes of Health (NIH)
Posted on 7/10/24

Limited Competition: Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional, RFA-HG-24-026, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH)
Posted on 7/10/24

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional), PAR-25-158, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH)
Posted on 11/25/24

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional), PAR-25-159, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), Office of Disease Prevention (ODP)
Posted on 11/25/24

The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional), PAR-25-292, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH)
Posted on 11/25/24

Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional), PAR-25-278, National Institute of Mental Health (NIMH), National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 11/21/24

Advancing Genomic Medicine Research (R01 Clinical Trial Optional), RFA-HG-25-002, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), National Cancer Institute (NCI)
Posted on 11/19/24

Advancing Genomic Medicine Research (R21 Clinical Trial Optional), RFA-HG-25-003, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), National Cancer Institute (NCI)
Posted on 11/19/24

Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed), RFA-HG-25-004, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH)
Posted on 11/19/24

NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required), PAR-25-049, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)
Posted on 11/7/24

Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional), PAR-25-117, National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), National Eye Institute (NEI), National Human Genome Research Institute (NHGRI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), Tribal Health Research Office (THRO)
Posted on 11/6/24

Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional), RFA-MD-24-012, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH)
Posted on 9/13/24

Limited Competition: NIMHD Initiative for Improving American Indian and Alaska Native Cancer Outcomes (U19 - Clinical Trial Optional), RFA-MD-24-009, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 6/17/24

Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional), PAR-24-231, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 6/10/24

Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions (P50 Clinical Trial Optional), RFA-HD-25-002, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 6/7/24

Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional), PAR-24-207, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI)
Posted on 5/13/24

Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Optional), RFA-MH-25-185, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), Office of AIDS Research (OAR), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 4/29/24

Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional), RFA-MH-25-186, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), Office of AIDS Research (OAR), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Drug Abuse (NIDA)
Posted on 4/29/24

Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional), PAR-24-110, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Cancer Institute (NCI), Office of Behavioral and Social Sciences Research (OBSSR)
Posted on 4/19/24

Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical Trial Required), RFA-MH-25-130, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 4/17/24

Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional), RFA-MH-25-190, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 4/3/24

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed), PAR-24-162, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 3/18/24

Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed), RFA-MD-24-005, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Sexual and Gender Minority Research Office (SGMRO)
Posted on 3/1/24

Translational Neural Devices (R61/R33 - Clinical Trial Optional), PAR-24-151, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 2/23/24

Limited Competition: Collaborative Study on the Genetics of Alcoholism (COGA) (U10 Clinical Trial Not Allowed), RFA-AA-24-003, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 2/14/24

Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional), PAR-24-118, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA)
Posted on 2/8/24

High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional), RFA-DA-25-060, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 1/17/24

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional), PAR-23-318, National Institutes of Health (NIH), Fogarty International Center (FIC), National Eye Institute (NEI), National Background Investigation Bureau, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Mental Health (NIMH), National Cancer Institute (NCI), Office of Dietary Supplements (ODS), Office of Research on Women's Health (ORWH)
Posted on 12/6/23

Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional), PAR-24-077, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Office of Behavioral and Social Sciences Research (OBSSR), Sexual and Gender Minority Research Office (SGMRO)
Posted on 11/30/23

Coordinating Center to Support Multi-Sectoral Preventive Interventions that Address Social Determinants of Health in Populations that Experience Health Disparities (U24, Clinical Trial Not Allowed), RFA-OD-24-006, National Institutes of Health (NIH), Office of Disease Prevention (ODP), National Institute on Minority Health and Health Disparities (NIMHD), Office of Data Science Strategy (ODSS)
Posted on 7/5/24

Multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities (UG3/UH3, Clinical Trial Required), PAR-24-053, National Institutes of Health (NIH), Office of Disease Prevention (ODP), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), Office of Dietary Supplements (ODS), Sexual and Gender Minority Research Office (SGMRO), Office of Research on Women's Health (ORWH)
Posted on 7/5/24

The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required), RFA-DA-25-027, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 2/13/24

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional), PAR-24-067, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 1/16/24

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional), PAR-24-068, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 1/16/24

2023

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional), RFA-NS-24-019, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 10/31/23

Career Enhancement Award to Advance Research on Firearm Injury and Mortality Prevention (K18 Independent Clinical Trial Not Allowed}, PAR-24-070, Office of Behavioral and Social Sciences Research (OBSSR), National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH), Sexual and Gender Minority Research Office (SGMRO)
Posted on 11/24/23

Career Enhancement Award to Advance Research on Firearm Injury and Mortality Prevention (K18 Independent Clinical Trial Required), PAR-24-073, Office of Behavioral and Social Sciences Research (OBSSR), National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR), Office of Disease Prevention (ODP), Sexual and Gender Minority Research Office (SGMRO)
Posted on 11/24/23

Advancing Genomic Medicine Research (R01 Clinical Trial Optional), RFA-HG-23-032, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI)
Posted on 11/6/23

Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed), RFA-HG-23-048, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)
Posted on 11/6/23

Advancing Genomic Medicine Research (R21 Clinical Trial Optional), RFA-HG-23-033, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI)
Posted on 11/6/23

Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional), PAR-23-293, National Institutes of Health (NIH), Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI), National Eye Institute (NEI), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI), National Institute on Minority Health and Health Disparities (NIMHD), Office of Research on Women's Health (ORWH)
Posted on 10/30/23

Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional), PAR-23-295, National Institutes of Health (NIH), Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Cancer Institute (NCI), Office of Data Science Strategy (ODSS), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women's Health (ORWH)
Posted on 10/30/23

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional), PAR-23-294, National Institutes of Health (NIH), Fogarty International Center (FIC), National Human Genome Research Institute (NHGRI), National Eye Institute (NEI), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI), Office of Behavioral and Social Sciences Research (OBSSR), Office of Research on Women's Health (ORWH)
Posted on 10/30/23

Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional), PAR-24-059, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH)
Posted on 8/11/23

Comprehensive Alcohol-HIV/AIDS Research Center (P60 Clinical Trial Optional), RFA-AA-23-004, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 8/10/23

Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required), RFA-MD-24-003, National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), Sexual and Gender Minority Research Office (SGMRO), Office of Research on Women's Health (ORWH)
Posted on 8/1/23

HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R01 Clinical Trial Optional), RFA-AA-23-005, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 11/14/23

HEAL Initiative: Developing an Evidence Base for Co-Occurring OUD-AUD Interventions (R34 Clinical Trial Optional), RFA-AA-23-006, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 11/14/23

Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional), RFA-MD-24-001, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 10/17/23

HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional), RFA-NS-24-021, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 10/7/23

Career Enhancement Award to Advance the Study of Intimate Partner Violence (IPV) in the Context of Maternal Morbidity and Mortality Research (K18 Clinical Trial Not Allowed), RFA-OD-24-001, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Nursing Research (NINR), Sexual and Gender Minority Research Office (SGMRO), Office of Disease Prevention (ODP), Office of Research on Women's Health (ORWH)
Posted on 10/4/23

Community-Engaged Health Equity Research in Neuroscience Initiative (R34 CT Not Allowed), RFA-NS-24-007, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 9/4/23

Community-Engaged Health Equity Research in Neuroscience Initiative (R01 CT Not Allowed), RFA-NS-24-006, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 9/4/23

Public Health Communication Messaging about the Continuum of Risk for Tobacco Products (U01 Clinical Trial Required), RFA-OD-23-021, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Office of Disease Prevention (ODP), National Cancer Institute (NCI)
Posted on 8/2/23

Network of Genomics-Enabled Learning Health Systems (gLHS) - Coordinating Center (U01 Clinical Trials Required), RFA-HG-23-042, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)
Posted on 8/1/23

Network of Genomics-Enabled Learning Health Systems (gLHS) - Clinical Sites (U01 Clinical Trial Required), RFA-HG-23-041, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)
Posted on 8/1/23

HEAL Initiative: Toward Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required), RFA-AT-24-003, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)
Posted on 6/9/23

Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional), RFA-HG-23-017, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Cancer Institute (NCI)
Posted on 6/5/23

Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional), RFA-HG-23-018, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA)
Posted on 6/5/23

Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional), RFA-MH-24-120, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 6/2/23

Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors – Clinical Centers (U01 Clinical Trial Not Allowed), RFA-DK-23-010, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 5/15/23

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-23-017, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Cancer Institute (NCI)
Posted on 5/4/23

Emergency Award: RADx-®UP Dissemination and Implementation (D&I) Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations (R01 Clinical Trial Optional), RFA-OD-23-051, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 5/2/23

HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional), RFA-NS-23-028, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 4/27/23

Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed), RFA-TR-23-011, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 4/20/23

Advancing Integrated Models (AIM) of Care to Improve Pregnancy Outcomes among Women Who Experience Persistent Disparities (R01 Clinical Trial Optional), RFA-NR-23-002, National Institutes of Health (NIH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 2/27/23

Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional), RFA-MD-23-004, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 2/15/23

Pilot Interventions to Integrate Social Care and Medical Care to Improve Health Equity (R01 Clinical Trial Required), RFA-DK-22-038, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 2/13/23

NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required), PAR-23-090, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 2/8/23

Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional), RFA-DA-24-037, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 2/7/23

Career Enhancement Award to Advance Research on Firearm Injury and Mortality Prevention (K18 Independent Clinical Trial Not Allowed), PAR-23-108, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/30/23

Career Enhancement Award to Advance Research on Firearm Injury and Mortality Prevention (K18 Independent Clinical Trial Required), PAR-23-107, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/30/23

Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 – Clinical Trial Optional), PAR-23-112, National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Minority Health and Health Disparities (NIMHD), National Eye Institute (NEI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/31/23

Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required), RFA-MH-23-170, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 1/12/23

NIDA Program Project Grant Applications (P01 Clinical Trial Optional), PAR-23-064, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 1/8/23

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required), RFA-NS-23-012, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), Office of The Director, National Institutes of Health (OD)
Posted on 1/9/23

2022

Research Centers in Minority Institutions (RCMI) (U54 Clinical Trial Optional), RFA-MD-23-001, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 12/30/22

Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (UG3/UH3 Clinical Trial Required), PAR-23-066, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), Sexual and Gender Minority Research Office (SGMRO)
Posted on 12/14/22

Interventions that Address Structural Racism to Reduce Kidney Health Disparities - Research Coordinating Center (U24 - Clinical Trial Not Allowed), RFA-DK-23-003, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 11/18/22

HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional), RFA-DA-23-059, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI)
Posted on 11/15/22

HEAL Initiative - Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program: Leadership and Data Co-ordinating Center (U01 Clinical Trial Optional), RFA-DA-23-060, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI)
Posted on 11/15/22

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed), RFA-DA-24-002, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 11/15/22

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required), RFA-OD-22-026, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)
Posted on 11/10/22

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed), RFA-OD-22-025, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)
Posted on 11/10/22

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required), RFA-OD-22-024, , National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)
Posted on 11/10/22

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed), RFA-OD-22-023, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)
Posted on 11/10/22

HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional), RFA-NS-22-069, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 11/4/22

Community Partnerships to Advance Science for Society (ComPASS): Coordination Center (U24 Clinical Trial Optional), RFA-RM-23-001, National Institutes of Health (NIH), Office of Strategic Coordination (Common Fund)
Posted on 10/3/22

Advancing Adolescent Tobacco Cessation Intervention Research (R34 Clinical Trial Optional), RFA-CA-22-042, National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA)
Posted on 10/3/22

Advancing Adolescent Tobacco Cessation Intervention Research (R01 Clinical Trial Required), RFA-CA-22-043, National Institutes of Health (NIH), National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA)
Posted on 10/3/22

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01 Clinical Trial Optional), RFA-DA-23-061, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 10/4/22

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R34 Clinical Trial Optional), RFA-DA-23-062, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 10/4/22

HEAL Initiative: HEAL Data2Action – Acceleration Projects (R33 Clinical Trial Not Allowed), RFA-DA-23-058, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 9/21/22

HEAL Initiative: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards (R61/R33, Clinical Trial Optional), RFA-DA-23-057, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 9/21/22

HEAL Initiative: Prevention and Management of Chronic Pain in Rural Populations (UG3/UH3, Clinical Trials Required), RFA-NR-23-001, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health Sciences (NIEHS), National Cancer Institute (NCI), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)
Posted on 9/16/22

Limited Competition: The NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL) (U24 Clinical Trial Not Allowed), RFA-HG-22-020, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI)
Posted on 9/16/22

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-22-202, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)National Institute on Drug Abuse (NIDA)
Posted on 9/1/22

Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional), PAR-22-200, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 9/1/22

Environmental influences on Child Health Outcomes (ECHO) Data Analysis Center (U24 Clinical Trial Not Allowed), RFA-OD-22-022, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS)
Posted on 8/30/22

Environmental influences on Child Health Outcomes (ECHO) Measurement Core (U24 Clinical Trial Not Allowed), RFA-OD-22-020, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS)
Posted on 8/30/22

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R21 Basic Experimental Studies with Humans Required), RFA-HD-23-033, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/29/22

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R21 Clinical Trial Not Allowed), RFA-HD-23-031, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/29/22

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Clinical Trial Not Allowed), RFA-HD-23-030, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/29/22

HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, and Neurodevelopmental Outcomes (R01 Basic Experimental Studies with Humans Required), RFA-HD-23-032, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/29/22

HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed), RFA-EB-22-002, National Institutes of Health (NIH), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 8/23/22

HEAL Initiative: Development and validation of virtual assessments to study children and caregivers in their natural environment (R01- Clinical Trial Not Allowed), RFA-DA-23-050, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/18/22

HEAL Initiative: Development and validation of virtual assessments to study children and caregivers in their natural environment (R01- Basic Experimental Studies with Humans Required), RFA-DA-23-055, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/18/22

Maternal Health Research Centers of Excellence Data Innovation and Coordinating Hub/Resource Center (U24 Clinical Trial Not Allowed), RFA-HD-23-036, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Office of AIDS Research (OAR), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Library of Medicine (NLM), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), Sexual and Gender Minority Research Office (SGMRO)
Posted on 8/11/22

AD/ADRD, Adverse Childhood Experiences, and Social Determinants of Health Ancillary Studies of Existing Longitudinal Cohorts (R01 - Clinical Trial Not Allowed), PAR-22-221, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA)
Posted on 8/10/22

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional), RFA-DA-23-032, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional), RFA-DA-23-031, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional), RFA-DA-23-029, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional), RFA-DA-23-028, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional), RFA-DA-23-026, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Coordination Center to Support Racial Equity and Substance Use Disparities Research (U24 Clinical Trial Not Allowed), RFA-DA-23-025, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional), RFA-DA-23-024, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional), RFA-DA-23-023, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional), RFA-DA-23-013, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/9/22

HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed), RFA-NS-22-070, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 8/9/22

HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R21 Clinical Trial Not Allowed), RFA-DE-23-016, National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/3/22

HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R01 Clinical Trial Not Allowed), RFA-DE-23-015, National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/3/22

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional), RFA-DA-23-054, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/3/22

HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional), RFA-DA-23-053, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH)
Posted on 8/3/22

HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional), RFA-NS-23-003, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 8/1/22

Interventions that Address Structural Racism to Reduce Kidney Health Disparities - (U01 - Clinical Trial Required), RFA-DK-22-014, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 7/27/22

Interventions that Address Structural Racism to Reduce Kidney Health Disparities - Research Coordinating Center (U24 - Clinical Trial Not Allowed), RFA-DK-22-015, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 7/27/22

HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers (R61/R33 Clinical Trial Required), RFA-DA-23-048, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 7/26/22

NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems (UG3/UH3 - Clinical Trial Optional), RFA-NS-22-053, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Nursing Research (NINR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 7/21/22

HEAL Initiative: Coordinated Pain Care in Health Care Systems Research Program - Coordinating Center (U24 Clinical Trial Not Allowed), RFA-NS-22-065, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 7/21/22

Expanding Collaborative Implementation Science to Address Social and Structural Determinants of Health and Improve HIV Outcomes (R01 Clinical Trial Required), RFA-MH-22-190, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA)
Posted on 7/20/22

Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional), PAR-22-210, National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 7/15/22

HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required), PAS-22-206, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 7/14/22

HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required), PAS-22-207, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 7/14/22

HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required), RFA-AT-23-002, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Advancing Translational Sciences (NCATS)
Posted on 7/13/22

HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional), RFA-AT-23-001, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 7/13/22

HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 - Clinical Trials Optional), RFA-DA-23-051, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Posted on 7/13/22

Understanding the Pathophysiology and Clinical Course of New-Onset Diabetes Following COVID-19 (U01 Clinical Trial Not Allowed), RFA-DK-22-016, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 7/13/22

HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL) (R01 Clinical Trial Required), RFA-DA-23-041, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 7/11/22

HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL): Resource Center (U24- Clinical Trial Optional), RFA-DA-23-042, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 7/11/22

New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI): Clinical/Community Field Centers (UG3/UH3 - Clinical Trial Not Allowed), RFA-HL-23-015, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH)
Posted on 7/6/22

HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed), RFA-DA-23-045, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 7/7/22

HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On (RM1 - Clinical Trial Optional), RFA-DA-23-046, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 7/6/22

Enabling SUD Digital Therapeutics Research to Improve Payor Adoption (R44- Clinical Trial Only), RFA-DA-23-018, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/29/22

NIDA Program Project Grant Applications (P01 Clinical Trial Optional), PAR-22-201, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/29/22

Therapeutic Development of Psychoplastogenic Compounds for Substance Use Disorders (R43/R44 - Clinical Trials Not Allowed), RFA-DA-23-017, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/23/22

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed), RFA-DA-23-052, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/14/22

Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional), RFA-DA-23-020, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/10/22

Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional), RFA-DA-23-019, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/10/22

Stakeholder Engagement Innovation Center for Advancing Health Equity in Type 2 Diabetes Research (U2C - Clinical Trial Not Allowed), RFA-DK-22-001, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 6/10/22

Data Management Coordinating Center for Diagnostic Centers of Excellence (U2C Clinical Trial Not Allowed), RFA-NS-22-051, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Human Genome Research Institute (NHGRI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Posted on 6/6/22

Research Coordinating Center to Support Climate Change and Health Community of Practice (U24 - Clinical Trial Not Allowed), RFA-ES-22-003, National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), Fogarty International Center (FIC), National Cancer Institute (NCI)
Posted on 6/6/22

NINDS Interdisciplinary Team Science Grant (RM1 Clinical Trial Optional), RFA-NS-22-036, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 5/18/22

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required), RFA-NS-22-071, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), Office of The Director, National Institutes of Health (OD)
Posted on 5/12/22

Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional), PAR-22-182, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/9/22

Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional), PAR-22-183, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/9/22

Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional), PAR-22-167, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of General Medical Sciences (NIGMS), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 5/9/22

Emergency Awards: HEAL Initiative: Coordinating Center for National Pain Scientists Career Development (R24 Clinical Trial Not Allowed), RFA-NS-22-060, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH)
Posted on 5/5/22

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed), RFA-DA-23-040, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 4/26/22

HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed), RFA-NS-22-052, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 4/22/22

Small Research Grants for Analysis, Curation, and/or Sharing of Down syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed), RFA-OD-22-008, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)
Posted on 4/8/22

Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required), RFA-DA-23-002, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 4/6/22

Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required), RFA-OD-22-010, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)
Posted on 4/5/22

Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed), RFA-OD-22-009, National Institutes of Health (NIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)
Posted on 4/5/22

INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed), RFA-OD-22-007, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke (NINDS), National Cancer Institute (NCI)
Posted on 4/5/22

Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional), PAR-22-145, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Mental Health (NIMH), National Library of Medicine (NLM)
Posted on 3/31/22

Implementation Research to Reduce Noncommunicable Disease (NCD) Burden in Low- and Middle-Income Countries (LMICs) and Tribal Nations During Critical Life Stages and Key Transition Periods (R01 Clinical Trial Optional), PAR-22-132, National Institutes of Health (NIH), Fogarty International Center (FIC), National Eye Institute (NEI), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)
Posted on 3/30/22

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional), RFA-DA-23-021, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/28/22

Understanding and Addressing Misinformation among Populations that Experience Health Disparities (R01 - Clinical Trials Optional), RFA-MD-22-008, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Cancer Institute (NCI)
Posted on 3/22/22

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed), PAR-22-138, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 3/15/22

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed), PAR-22-137, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Environmental Health Sciences (NIEHS), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 3/15/22

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional), PAR-22-133, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/15/22

Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R21 - Clinical Trial Not Allowed), RFA-DA-23-009, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/14/22

Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R34 - Clinical Trial Optional), RFA-DA-23-010, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/14/22

Addressing Mental Health Disparities Research Gaps: Aggregating and Mining Existing Data Sets for Secondary Analyses (R01 Clinical Trial Not Allowed), RFA-MH-22-200, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/11/22

Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54 Clinical Trial Optional), RFA-OD-22-004, National Institutes of Health (NIH), , U.S. Food and Drug Administration (FDA), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS)
Posted on 3/8/22

Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54 Clinical Trial Not Allowed), RFA-OD-22-003, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA)
Posted on 3/8/22

Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (UG3/UH3 Clinical Trial Optional), PAR-22-115, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 3/4/22

Coordinating Center to Support Research on Community Level Interventions for Firearm and Related Violence, Injury and Mortality Prevention (CLIF-VP) (U24 Clinical Trial Not Allowed), PAR-22-120, National Institutes of Health (NIH), Office of Behavioral and Social Sciences Research (OBSSR), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 3/4/22

Limited Competition for the Continuation of the Data Coordinating Center for the Diabetic Foot Consortium (U24 Clinical Trial Optional), RFA-DK-21-505, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 3/3/22

Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 Clinical Trial Required), RFA-DA-23-006, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 2/25/22

Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R34 Clinical Trial Required), RFA-DA-23-007, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 2/25/22

Emergency Awards: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trial Optional), RFA-OD-22-005, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 2/17/22

Emergency Award: RADx-UP Community-Engaged Research on Rapid SARS-CoV-2 Testing among Underserved and Vulnerable Populations (U01 Clinical Trial Optional), RFA-OD-22-006, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Human Genome Research Institute (NHGRI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of General Medical Sciences (NIGMS), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 2/17/22

Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 Clinical Trial Optional), RFA-DA-23-003, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 2/11/22

HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional), RFA-NS-22-050, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 2/8/22

HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed), RFA-NS-22-018, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 2/4/22

HEAL Initiative: Human Pain-associated Genes & Cells Data Coordination and Integration Center (U24 Clinical Trial Not Allowed), RFA-NS-22-021, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 2/1/22

Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required), PAR-22-112, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 1/31/22

Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Optional), PAR-22-113, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 1/31/22

Advancing Integrated Models (AIM) of Care to Improve Maternal Health Outcomes among Women Who Experience Persistent Disparities (R01 Clinical Trial Required), RFA-NR-22-002, National Institutes of Health (NIH), National Institute of Nursing Research (NINR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 1/26/22

HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed), RFA-DE-22-011, National Institutes of Health (NIH), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 1/21/22

Emergency Award HEAL Initiative: Optimizing Existing Evidence-Based Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional), RFA-MH-22-175, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/21/22

Emergency Award HEAL Initiative: Developing and Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional), RFA-MH-22-176, National Institutes of Health (NIH), National Institute of Mental Health (NIMH), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/21/22

Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed), RFA-TR-22-013, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 1/20/22

HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required), RFA-NS-22-037, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 1/20/22

Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 Clinical Trial Optional), RFA-MD-22-007, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH)
Posted on 1/20/22

Emergency Awards: HEAL Initiative-Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Research Network (ERN) (U24 Clinical Trial Not Allowed), RFA-TR-22-012, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Mental Health (NIMH), National Center for Advancing Translational Sciences (NCATS), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/19/22

Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional), RFA-DA-22-038, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 1/10/22

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional), RFA-DA-22-037, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 1/10/22

HEAL Initiative: National K12 Clinical Pain Career Development Program (K12 Clinical Trial Not Allowed), RFA-NS-22-045, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Cancer Institute (NCI)
Posted on 1/10/22

HEAL Initiative: Coordinating Center for National Pain Scientists Career Development (R24 Clinical Trial Not Allowed), RFA-NS-22-046, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/10/22

HEAL Initiative: Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN) (UC2 Clinical Trial Not Allowed), RFA-AR-22-009, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 1/10/22

HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed), RFA-NS-22-034, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 1/7/22

2021

HEAL Initiative: HEAL Data2Action Modeling and Economic Resource Center (U24 Clinical Trial Optional), RFA-DA-049, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/30/21

HEAL Initiative: HEAL Data2Action Research Adoption Support Center (U2C Clinical Trial Optional), RFA-DA-22-050, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/30/21

HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional), RFA-DA-22-051, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/30/21

HEAL Initiative: Pilot & Feasibility Trials to Improve Prevention and Treatment Service Delivery for Polysubstance Use (R34 Clinical Trial Optional), RFA-DA-22-048, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/29/21

HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional), RFA-DA-22-047, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/29/21

HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders (R01 Clinical Trial Optional), RFA-DA-22-046, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/29/21

HEAL Initiative: Research Networks for the Study of Recovery Support Services for Persons Treated with Medications for Opioid Use Disorder (R24 Clinical Trial Optional), RFA-DA-22-043, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/29/21

HEAL Initiative: Harm Reduction Policies, Practices, and Modes of Delivery for Persons with Substance Use Disorders: Coordination Center (R24 Clinical Trial Optional), RFA-DA-22-042, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Posted on 12/29/21

HEAL Initiative: Planning Grants for Efficacy or Effectiveness Trials of Recovery Support Services for Individuals Treated with Medications for Opioid Use Disorder (R34 Clinical Trial Optional), RFA-DA-22-034, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/29/21

HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed), RFA-DA-22-045, National Institutes of Health, National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/20/21

HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed), RFA-DA-22-044, National Institutes of Health, National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH)
Posted on 12/20/21

Center for Rapid Surveillance of Tobacco (CRST) to Assess Changes in Use Behaviors, Product Marketing, and the Marketplace (U01 Clinical Trial Not Allowed), RFA-OD-22-002, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), National Cancer Institute (NCI)
Posted on 12/13/21

Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional), PAR-21-358, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Nursing Research (NINR), National Cancer Institute (NCI)
Posted on 12/13/21

Research Centers in Minority Institutions (RCMI) (U54 Clinical Trials Optional), RFA-MD-22-002, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 11/23/21

NIH HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 Clinical Trials Optional), RFA-DA-22-036, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Aging (NIA), National Institute of Mental Health (NIMH)
Posted on 11/16/21

Patient-Clinician Relationship: Improving Health Outcomes in Populations that Experience Health Care Disparities (R01 Clinical Trial Optional), PAR-22-064, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Deafness and Other Communication Disorders (NIDCD)
Posted on 11/16/21

Understanding Place-Based Health Inequalities in Mid-Life (R01 Clinical Trial Not Allowed), RFA-AG-23-004, National Institutes of Health (NIH)
Posted on 11/16/21

HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management (R61/R33, Clinical Trial Required), RFA-AT-22-003, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS)
Posted on 11/16/21

Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required), RFA-MH-22-150, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 11/15/21

Home and Community-Based Physical Activity Interventions to Improve the Health of Wheelchair Users (R01 Clinical Trial Required), RFA-HD-22-017, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Posted on 10/29/21

HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required), RFA-AT-22-005, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Advancing Translational Sciences (NCATS)
Posted on 10/29/21

HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional), RFA-AT-22-004, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 10/29/21

Clinical Research Education and Career Development (CRECD) Program (R25-Independent Clinical Trial Not Allowed), PAR-21-347, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Nursing Research (NINR)
Posted on 10/19/21

NIH Health Care Systems Research Collaboratory - Pragmatic and Implementation Trials of Embedded Interventions (UG3/UH3, Clinical Trials Optional), RFA-AT-22-001, National Institutes of Health (NIH), National Center for Complementary and Integrative Health (NCCIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 10/18/21

HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required), RFA-NS-22-002, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Eye Institute (NEI), National Institute on Aging (NIA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Institute on Minority Health and Health Disparities (NIMHD), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS), National Cancer Institute (NCI)
Posted on 10/8/21

Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional), RFA-ES-21-007, National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS)
Posted on 10/6/21

Pediatric Obesity Discovery Science Research to Improve Understanding of Risk and Causal Mechanisms for Obesity in Early Life (R01 Clinical Trial Optional), RFA-DK-21-025, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 10/4/21

HEAL initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression Without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development) (UG3/UH3 Clinical Trials Not Allowed), RFA-HL-22-013, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA)
Posted on 9/30/21

Investigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Exploratory/Developmental Research Grant Award (R21 Clinical Trial Not Allowed), RFA-OD-21-007, National Institutes of Health (NIH), Office of The Director, National Institutes of Health (OD), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP), National Cancer Institute (NCI)
Posted on 9/24/21

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional), PAS-21-270, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 9/10/21

An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immunogenicity in Severe Hemophilia A: Hemophilia A Analytical Cohort Research Program (UG3/UH3 Clinical Trial Not Allowed), RFA-HL-22-004, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Posted on 9/9/21

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional), RFA-DA-22-040, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 9/8/21

Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R01 - Clinical Trial Optional), RFA-DA-22-028, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 9/8/21

Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R21 - Clinical Trial Optional), RFA-DA-22-039, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 9/8/21

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional), PAR-22-027, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 9/3/21

HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional), RFA-NS-22-016, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Dental and Craniofacial Research (NIDCR), National Center for Complementary and Integrative Health (NCCIH), National Center for Advancing Translational Sciences (NCATS)
Posted on 8/31/21

Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3 Clinical Trial Optional), RFA-DA-22-022, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/12/21

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional), PAR-21-303, National Institutes of Health (NIH)
Posted on 8/4/21

Imaging - Science Track Award for Research Transition (I/START) (R03- Basic Experimental Studies with Humans Required), PAR-21-309, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/2/21

Imaging - Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional), PAR-21-310, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 8/2/21

Advancing Validated Drug Targets for Substance Use Disorders (R41/R42 - Clinical Trial Not Allowed), RFA-DA-22-018, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 7/29/21

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed), RFA-DA-22-033, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 7/21/21

Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional), RFA-DA-23-001, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 7/9/21

HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed), RFA-DA-22-032, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 7/6/21

HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed), RFA-DA-22-031, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Complementary and Integrative Health (NCCIH)
Posted on 7/6/21

Exploratory Studies to Investigate the Mechanisms of Interrelationship between Sleep and Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans Required), RFA-DA-22-029, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/28/21

The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional), PAR-21-275, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Aging (NIA), National Institute on Drug Abuse (NIDA), National Institute of Environmental Health Sciences (NIEHS), National Institute of Mental Health (NIMH), National Cancer Institute (NCI)
Posted on 6/25/21

Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R34 Clinical Trial Required), RFA-MH-21-241, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 6/25/21

Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R01 Clinical Trial Required), RFA-MH-21-240, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 6/25/21

Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 - Clinical Trials Not Allowed), RFA-DA-22-003, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/23/21

Large Scale Mapping and/or Molecular Profiling of Ensembles and/or Cell-Types Mediating Opioid Action in the Rodent Brain (R01 - Clinical Trial Not Allowed), RFA-DA-22-011, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/21/21

Organoid Modeling of Neural Stimulants and HIV Comorbidity of Human Brain (R01- Clinical Trial Optional), RFA-DA-22-009, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/17/21

PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional), RFA-DA-22-017, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/16/21

NIDA Animal Genomics Program (U01 - Clinical Trial Not Allowed), PAR-21-244, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/10/21

Exploratory Studies to Investigate the Mechanisms of Interrelationship Between Sleep and Substance Use Disorders (R61/R33 Clinical Trials Not Allowed), RFA-DA-22-016, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 6/4/21

Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation (R01 Clinical Trial Optional), RFA-DA-22-012, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/24/21

Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Basic Experimental Studies with Humans Required), RFA-DA-22-030, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/24/21

Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Basic Experimental Studies with Humans Required), RFA-DA-22-024, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/24/21

Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 Clinical Trial Not Allowed), RFA-DA-22-007, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/24/21

Mechanistic studies on the Impact of Social Inequality on the Substance Use Trajectory (R21 - Clinical Trial Not Allowed), RFA-DA-22-005, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/24/21

NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required), PAR-21-237, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Posted on 5/19/21

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional), PA-21-180, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 5/19/21

Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required), PA-21-205, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 5/10/21

Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional), RFA-DA-22-001, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 4/27/21

Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required), RFA-MH-21-230, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 4/19/21

NIMHD Multiple Chronic Disease Disparities Research Coordinating Center (RCC) (U24 Clinical Trial Not Allowed), RFA-MD-21-008, National Institutes of Health (NIH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 4/14/21

Centers for Multiple Chronic Diseases Associated with Health Disparities: Prevention, Treatment, and Management (P50 Clinical Trial Required), RFA-MD-21-007, National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 4/14/21

Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional), RFA-OD-21-009, National Institutes of Health (NIH)
Posted on 4/13/21

Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations - RADx-UP Phase II (U01 Clinical Trial Optional), RFA-OD-21-008, National Institutes of Health (NIH)
Posted on 4/13/21

Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed), RFA-DA-22-021, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 4/8/21

Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R43/R44 - Clinical Trial Not Allowed), RFA-DA-22-019, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 4/8/21

Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed), PAR-21-213, National Institutes of Health (NIH) National Institute on Aging (NIA), National Eye Institute (NEI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute on Minority Health and Health Disparities (NIMHD)
Posted on 4/6/21

Limited Competition Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed), RFA-DA-22-002, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 4/2/21

Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional), PAR-21-208, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/26/21

Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional), PAR-21-183, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Posted on 3/23/21

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional), RFA-MD-21-004, National Institutes of Health (NIH)
Posted on 3/23/21

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required), PAR-21-132, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Posted on 3/2/21

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-21-002, National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA)
Posted on 2/17/21

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed), RFA-AA-21-003, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 2/5/21

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed), RFA-AA-21-002, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism. (NIAAA)
Posted on 2/5/21

SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed), RFA-AA-21-004, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Posted on 2/5/21

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed), RFA-DA-22-004, National Institutes of Health, National Institute on Drug Abuse (NIDA)
Posted on 2/1/21

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed), PAR-21-062, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Posted on 1/11/21

HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required), RFA-DA-21-030, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Mental Health; National Center for Complement
Posted on 1/11/21

HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Coordination and Dissemination Center (R24 Clinical Trial Optional), RFA-DA-21-029, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Mental Health; National Center for Complement
Posted on 1/11/21

HEAL Initiative: HEALthy Brain and Child Development Study (Collaborative U01- Clinical Trial Not Allowed), RFA-DA-21-020, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Biomedical Imaging and Bioengineering; National Institute of Child Health and Human Development; National Institute
Posted on 1/11/21

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the NIDDK (R21 Clinical Trial Not Allowed), PAR-21-062, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases
Posted on 1/12/21

Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional), PAS-21-031, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases
Posted on 1/8/21

2020

Multi-Omics for Health and Disease - Data Analysis and Coordination Center (U01 Clinical Trial Not Allowed), RFA-HG-22-010, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)
Posted on 9/7/20

Multi-Omics for Health and Disease - 'Omics Production Centers (U01 Clinical Trial Not Allowed), RFA-HG-22-009, National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)
Posted on 9/7/20

Multi-Omics for Health and Disease - Disease Study Sites (U01 Clinical Trial Optional), RFA-HG-22-008, National Institutes of Health (NIH), National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), National Institute of Environmental Health, Sciences (NIEHS), National Cancer Institute (NCI)
Posted on 9/7/20

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional), PAR-21-092, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/21/20

Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with, RFA-OD-20-023, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases;
Posted on 8/6/20

Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional), RFA-OD-20-022, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Aging; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Deafness and Other Communication Diso
Posted on 8/6/20

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed), RFA-OD-20-021, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Nat
Posted on 8/6/20

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed), RFA-OD-20-020, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Nat
Posted on 8/6/20

Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed), RFA-OD-20-019, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of
Posted on 8/6/20

Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed), RFA-OD-20-018, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute of Dental and Craniofacial Research;
Posted on 8/6/20

Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed), RFA-OD-20-017, National Institutes of Health; Office of The Director, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute of Arthritis and Musculosk
Posted on 8/6/20

Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional), RFA-OD-20-016, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Disea
Posted on 8/6/20

Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed), RFA-OD-20-015, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Drug Abuse; National Institute of Environmental Health Sciences; National Institute of General Medical Sciences; National Library of Medicine; This
Posted on 8/6/20

Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed), RFA-OD-20-014, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Nationa
Posted on 8/6/20

Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional), PAR-20-286, National Institutes of Health; National Institute of Mental Health
Posted on 8/5/20

Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional), PAR-20-279, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 7/27/20

NIDA Core Center of Excellence Grant Program (P30 Clinical Trial Optional), PAR-20-267, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/17/20

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional), PAR-20-249, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/1/20

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional), PAR-20-237, National Institutes of Health; National Institute on Minority Health and Health Disparities; National Eye Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health
Posted on 6/17/20

Improving Smoking Cessation Interventions among People Living with HIV (R21 Clinical Trial Optional), RFA-CA-20-036, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse
Posted on 6/10/20

Improving Smoking Cessation Interventions among People Living with HIV (R01 Clinical Trial Optional), RFA-CA-20-035, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities
Posted on 6/10/20

Advancing Genomic Medicine Research (Clinical Trial Optional) (R21), RFA-HG-20-037, National Institutes of Health; National Human Genome Research Institute
Posted on 6/4/20

Advancing Genomic Medicine Research (Clinical Trial Optional) (R01), RFA-HG-20-036, National Institutes of Health; National Human Genome Research Institute
Posted on 6/4/20

Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional), RFA-OD-20-013, National Institutes of Health; Office of The Director, National Institutes of Health; National Institute on Minority Health and Health Disparities; National Institute on Aging; National Eye Institute; National Heart, Lung, and Blood Institute; National Hu
Posted on 6/12/20

NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional), PAR-20-221, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/1/20

Post-Acute Interventions for the Treatment of Anorexia Nervosa (R34 Clinical Trial Required), RFA-MH-20-500, National Institutes of Health; National Institute of Mental Health
Posted on 4/15/20

NIDA Small Research Grant Program (R03 Clinical Trial Required), PA-20-146, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/24/20

Implementing the HIV Service Cascade for Justice-Involved Populations (U01 Clinical Trial Required), RFA-DA-20-028, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/19/20

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required), RFA-OD-20-011, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; U.S. Food and Drug Administration, Center for Tobacco Products
Posted on 2/7/20

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required), RFA-OD-20-010, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 2/7/20

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed), RFA-OD-20-009, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 2/7/20

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed), RFA-OD-20-008, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 2/7/20

Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional), PAR-20-092, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/24/20

Genomic Community Resources (U24 Clinical Trial Not Allowed), PAR-20-100, National Institutes of Health; National Human Genome Research Institute; National Cancer Institute
Posted on 1/23/20

2019

Safety and Feasibility Trials for Rapid-Acting Interventions for Severe Suicide Risk (R01 Clinical Trial Required), RFA-MH-20-345, National Institutes of Health; National Institute of Mental Health
Posted on 11/25/19

Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R01 Clinical Trial Optional), RFA-MH-20-505, National Institutes of Health; National Institute of Mental Health
Posted on 11/25/19

Practice-Based Research for Implementing Scalable Evidence-Based Prevention Interventions in Primary Care Settings (R34 Clinical Trial Required), RFA-MH-20-506, National Institutes of Health; National Institute of Mental Health
Posted on 11/25/19

Enhancing Suicide Prevention in Emergency Care via Telehealth (R01 Clinical Trial Optional), RFA-MH-20-226, National Institutes of Health; National Institute of Mental Health
Posted on 11/19/19

Early Psychosis Intervention Network (EPINET): Practice-Based Research to Improve Treatment Outcomes (R01 Clinical Trial Optional), RFA-MH-20-205, National Institutes of Health; National Institute of Mental Health
Posted on 11/18/19

Dysregulation and Proximal Risk for Suicide (R01 Clinical Trial Optional), RFA-MH-20-327, National Institutes of Health; National Institute of Mental Health
Posted on 11/8/19

Dysregulation and Proximal Risk for Suicide (R21 Clinical Trial Optional), RFA-MH-20-326, National Institutes of Health; National Institute of Mental Health
Posted on 11/8/19

Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (Collaborative U01 Clinical Trial Not Allowed), PAR-20-027, National Institutes of Health; National Institute of Mental Health
Posted on 10/20/19

Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (U01 Clinical Trial Not Allowed), PAR-20-026, National Institutes of Health; National Institute of Mental Health
Posted on 10/2/19

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-19-028, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Environment
Posted on 9/25/19

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional), PAR-19-368, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute
Posted on 9/9/19

The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required), RFA-DA-20-024, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/4/19

NIDA Program Project Grant Applications (P01 Clinical Trial Optional), PAR-19-345, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/14/19

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-19-327, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/1/19

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01-Clinical Trial Optional), PAR-19-318, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/26/19

Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed), RFA-DA-20-023, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/10/19

Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional), PAR-19-310, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/28/19

PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional), RFA-DA-20-013, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/16/19

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional), PAR-19-259, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/24/19

Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed), RFA-HL-20-014, National Institutes of Health; National Heart, Lung, and Blood Institute; National Center for Advanced of Translational Sciences
Posted on 4/4/19

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis, Informatics and Resource Center (U24 Clinical Trial Not Allowed), RFA-DA-20-003, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 4/3/19

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Linked Research Project Sites (Collaborative U01 Clinical Trial Not Allowed), RFA-DA-20-002, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 4/3/19

Limited Competition for Adolescent Brain Cognitive Development (ABCD) Study - Coordinating Center (U24 Clinical Trial Not Allowed), RFA-DA-20-004, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 4/3/19

Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required), PAR-19-236, National Institutes of Health; National Institute of Mental Health
Posted on 4/2/19

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required), PAR-19-235, National Institutes of Health; National Institute of Mental Health
Posted on 4/2/19

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional), PAR-19-212, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 3/7/19

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), PAR-19-213, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 3/7/19

Centers of Excellence in Genomic Science (RM1 Clinical Trials Optional), PAR-19-204, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health
Posted on 2/28/19

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-19-019, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 2/21/19

Refinement and Testing of Interventions to Sustain ADHD Treatment Effects Across Settings and Developmental Transitions (R34 Clinical Trial Required), RFA-MH-20-100, National Institutes of Health; National Institute of Mental Health
Posted on 2/4/19

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed), PAR-19-162, National Institutes of Health; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities; National Institute of Mental Health; National Cancer Institute; National Center for Complementary and Integrative Health; Nation
Posted on 1/9/19

Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed), PAR-19-163, National Institutes of Health; National Institute on Drug Abuse; National Institute of Neurological Disorders and Stroke; National Institute on Minority Health and Health Disparities; National Institute of Mental Health; National Cancer Institute; Eunice
Posted on 1/9/19

2018

Laboratories for Early Clinical Evaluation of Pharmacotherapies for Substance Use Disorders (UG1 Clinical Trial Required), RFA-DA-19-018, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/21/18

HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) (UG3/UH3 Clinical Trial Required), RFA-DA-19-035, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute of Child Health and Huma
Posted on 12/10/18

HEAL Initiative: Effectiveness Trials to Optimize, Implement, Scale, and Sustain the Collaborative Care Model for Individuals with Opioid Use Disorders and Mental Health Conditions (U01 Clinical Trial Required), RFA-MH-19-525, National Institutes of Health; National Institute of Mental Health; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; National Institute of Nursing Research; National Institute on Minority H
Posted on 12/10/18

HEAL Initiative: Coordinating Center to Support NIDA Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) Initiative (U24 Clinical Trial Not Allowed), RFA-DA-19-034, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute of Child Health and Huma
Posted on 12/10/18

HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Clinical Research Centers (UG1 Clinical Trial Optional), RFA-DA-19-025, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 12/10/18

HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Coordination and Translation Center (U2C Clinical Trial Optional), RFA-DA-19-024, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 12/10/18

HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Methodology and Advanced Analytics Resource Center (U2C Clinical Trial Not Allowed), RFA-DA-19-023, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 12/10/18

Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed), PA-19-043, National Institutes of Health; National Human Genome Research Institute
Posted on 10/31/18

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional), PAR-19-064, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 11/9/18

HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis (Data Coordinating Center) (UM1 - Clinical Trials Not Allowed), RFA-DA-19-017, National Institutes of Health; Substance Abuse and Mental Health Services Administration; National Institute on Drug Abuse
Posted on 9/19/18

HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional), PAS-18-915, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/10/18

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional), PA-18-916, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/10/18

Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional), PAR-18-918, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/10/18

Responding to Opioid Use Disorders (OUD) in Tribal Communities in the Context of SAMHSA and CDC Funding (R61/R33 - Clinical Trials Optional), RFA-DA-19-013, National Institutes of Health; National Institute on Drug Abuse; Office of Behavioral and Social Sciences Research; Tribal Health Research Office
Posted on 9/18/18

HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis (Research Sites) (UM1 - Clinical Trial Required), RFA-DA-19-016, National Institutes of Health; Substance Abuse and Mental Health Services Administration; National Institute on Drug Abuse
Posted on 9/19/18

The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Optional), RFA-DA-19-008, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/26/18

Dysregulation and Proximal Risk for Suicide FOA (R01 Clinical Trial Optional), RFA-MH-19-211, National Institutes of Health; National Institute of Mental Health
Posted on 10/3/18

Dysregulation and Proximal Risk for Suicide (R21 Clinical Trial Optional), RFA-MH-19-210, National Institutes of Health; National Institute of Mental Health
Posted on 10/3/18

Improving Smoking Cessation Interventions among People Living with HIV (R21 Clinical Trial Optional), RFA-CA-18-028, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse
Posted on 8/24/18

Improving Smoking Cessation Interventions among People Living with HIV (R01 Clinical Trial Optional), RFA-CA-18-027, National Institutes of Health; National Cancer Institute; National Institute on Drug Abuse; National Institute on Minority Health and Health Disparities
Posted on 8/24/18

Early Psychosis Intervention Network (EPINET): Data Coordinating Center (U24 Clinical Trial Not Allowed), RFA-MH-19-151, National Institutes of Health; National Institute of Mental Health
Posted on 7/30/18

Early Psychosis Intervention Network (EPINET): Practice-Based Research to Improve Treatment Outcomes (R01 Clinical Trial Optional), RFA-MH-19-150, National Institutes of Health; National Institute of Mental Health
Posted on 7/30/18

Novel Approaches for Relating Genetic Variation to Function and Disease (R21 Clinical Trial Not Allowed), PA-18-867, National Institutes of Health; National Human Genome Research Institute
Posted on 7/23/18

Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed), PA-18-868, National Institutes of Health; National Human Genome Research Institute
Posted on 7/23/18

Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (Collaborative U01 Clinical Trial Not Allowed), RFA-MH-19-201, National Institutes of Health; National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development
Posted on 6/7/18

Rare Genetic Syndromes as a Window into the Genetic Architecture of Mental Disorders (U01 Clinical Trial Not Allowed), RFA-MH-19-200, National Institutes of Health; National Institute of Mental Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development
Posted on 6/7/18

Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (U01 Clinical Trial Not Allowed), PAR-18-789, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/16/18

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed), RFA-OD-18-005, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; National Institute of Environmental Health Sciences
Posted on 5/15/18

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required), RFA-OD-18-006, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse
Posted on 5/15/18

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required), RFA-OD-18-008, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse
Posted on 5/15/18

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed), RFA-OD-18-007, National Institutes of Health; U.S. Food and Drug Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; National Institute of Environmental Health Sciences
Posted on 5/15/18

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 - Clinical Trial Optional), PA-18-780, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/10/18

International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional), PA-18-773, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/9/18

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional), PA-18-775, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/9/18

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional), PAR-18-746, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/6/18

Investigator-Initiated Genomic Medicine Research (R01 Clinical Trial Optional), PAR-18-735, National Institutes of Health; National Human Genome Research Institute
Posted on 4/2/18

Investigator-Initiated Genomic Medicine Research (R21 Clinical Trial Optional), PAR-18-736, National Institutes of Health; National Human Genome Research Institute
Posted on 4/2/18

Coordinating Center to Support NIDA Rural Opioid HIV and Comorbidity Initiative (U24 - Clinical Trial Not Allowed), RFA-DA-19-004, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/20/18

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01, Clinical Trial Optional), RFA-DA-18-022, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/14/18

Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment (R61/R33 Clinical Trial Required), RFA-DA-19-005, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/5/18

NIDA Small Research Grant Program (R03 Clinical Trial Required), PA-18-634, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/6/18

NIDA Small Research Grant Program (R03 Clinical Trial Required), PA-18-626, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/2/18

NIDA Academic Research Enhancement Award (R15, Clinical Trials Required), PA-18-627, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/2/18

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01, Clinical Trial Optional), PA-18-569, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 1/11/18

International Research Collaboration on Drug Abuse and Addiction Research (R01, Clinical Trial Optional), PA-18-568, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/18

2017

Improving Implementation of Seek, Test, Treat and Retain Strategies among People Who Inject Drugs in Low to Middle Income Countries (R01-Clinical Trial Required), RFA-DA-18-017, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/22/17

Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01- Clinical Trial Not Allowed), RFA-DA-18-023, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/21/17

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional), PAR-18-527, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/18/17

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 ), PAR-18-510, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/18/17

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 Clinical Trial Optional ), PAR-18-509, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/18/17

Device-Based Treatments for Substance Use Disorders (UG3/UH3) (Clinical Trial Optional), PAR-18-494, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 12/15/17

Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional), RFA-DA-19-002, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/14/17

Pilot Effectiveness Trials for Post-Acute Interventions and Serivces to Optimize Longer-Term Outcomes (R34-Clinical Trials Required), PAR-18-431, National Institutes of Health; National Institute of Mental Health
Posted on 12/6/17

Effectiveness Trials for Post-Acute Interventions and Services and Services to Optimize Longer-Term Outcomes (R01-Clinical Trials Required), PAR-18-430, National Institutes of Health; National Institute of Mental Health
Posted on 12/1/17

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3, Clinical Trial Optional), RFA-DA-18-020, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/6/17

NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional), RFA-DA-18-019, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/6/17

NIDA Core Center of Excellence Grant Program (P30 Clinical Trial Optional), PAR-18-225, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/30/17

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional), PAR-18-224, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/30/17

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional), PAR-18-226, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/30/17

NIDA Program Project Grant Applications (P01, Clinical Trial Optional), PAR-18-425, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/29/17

Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3 Clinical Trial Optional), PAR-18-221, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/29/17

Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required), PAR-18-233, National Institutes of Health; National Institute of Mental Health
Posted on 11/21/17

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required), PAR-18-232, National Institutes of Health; National Institute of Mental Health
Posted on 11/21/17

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional), PAR-18-219, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/21/17

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01 Clinical Trial Optional), PAR-18-218, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/21/17

Ancillary Studies to Identify Behavioral and/or Psychological Phenotypes Contributing to Obesity (R01 Clinical Trial Optional), PAR-18-105, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; Office of Behavioral and Social Sciences Research
Posted on 11/21/17

Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional), RFA-OD-18-001, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 11/20/17

Tobacco Regulatory Science (R01 Clinical Trial Optional), RFA-OD-18-002, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 11/20/17

Tobacco Regulatory Science (R21 Clinical Trial Optional), RFA-OD-18-003, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 11/20/17

Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional), PAR-18-082, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/17/17

Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional), PAR-18-081, National Institutes of Health; National Institute on Drug Abuse; National Institute of Biomedical Imaging and Bioengineering
Posted on 11/17/17

Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33), RFA-AT-18-002, National Institutes of Health; National Center for Complementary and Integrative Health
Posted on 11/16/17

AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional), PA-18-072, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/15/17

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 Clinical Trial Optional), PA-18-071, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/15/17

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21 Clinical Trial Optional), PA-18-070, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 11/15/17

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03 Clinical Trial Optional), PA-18-069, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 11/15/17

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34 Clinical Trial Optional), PA-18-068, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 11/15/17

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34 Clinical Trial Optional), PA-18-067, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 11/15/17

International Research Collaboration on Drug Abuse and Addiction Research (R21 Clinical Trial Optional), PA-18-066, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/15/17

International Research Collaboration on Drug Abuse and Addiction Research (R03 Clinical Trial Optional), PA-18-065, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/15/17

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01- Clinical Trial Required), RFA-MH-18-707, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required), RFA-MH-18-706, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33- Clinical Trial Required), RFA-MH-18-705, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33- Clinical Trial Required), RFA-MH-18-704, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Early Stage Testing of Pharmacologic or Device -based Interventions for the Treatment of Mental Health Disorders (R33- Clinical Trial Required), RFA-MH-18-703, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33-Clinical Trial Required), RFA-MH-18-702, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01- Clinical Trial Required), RFA-MH-18-701, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01-Clinical Trial Required), RFA-MH-18-700, National Institutes of Health; National Institute of Mental Health
Posted on 11/14/17

Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional), PAR-18-064, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute
Posted on 11/8/17

Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional), PA-18-078, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/3/17

Neuroscience Research on Drug Abuse (R01 Clinical Trial Optional), PA-18-060, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/3/17

Prescription Drug Abuse (R21 Clinical Trial Optional), PA-18-076, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/2/17

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21 Clinical Trial Optional), PA-18-075, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/2/17

Behavioral and Integrative Treatment Development Program (R03 Clinical Trial Optional), PA-18-074, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 11/2/17

Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), PA-18-073, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 11/2/17

Prescription Drug Abuse (R01 Clinical Trial Optional), PA-18-058, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/2/17

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01 Clinical Trial Optional), PA-18-056, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/2/17

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional), PA-18-055, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 11/2/17

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional), PAR-18-062, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism
Posted on 11/1/17

The Application of Big Data Analytics to Drug Abuse Research (R01 Clinical Trial Optional), PA-18-057, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/1/17

Pharmacogenomics of Anti-retroviral Therapy in People Who Inject Drugs (R01), RFA-DA-18-014, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/3/17

Tobacco Regulatory Science Small Grant Program for New Investigators (R03), RFA-OD-17-012, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 7/20/17

Tobacco Regulatory Science (R21), RFA-OD-17-014, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 7/20/17

Tobacco Regulatory Science (R01), RFA-OD-17-013, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 7/20/17

The NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space (AnVIL) (U24), RFA-HG-17-011, National Institutes of Health; National Human Genome Research Institute
Posted on 7/17/17

Limited Competition Cohort Studies of HIV/AIDS and Substance Abuse (U01), RFA-DA-18-011, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/14/17

HIV/HCV Co-Infections in Substance Abusers (R01), PAS-17-311, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/13/17

Addressing Suicide Research Gaps: Understanding Mortality Outcomes (R01), RFA-MH-18-410, National Institutes of Health; National Institute of Mental Health; National Center for Complementary and Integrative Health; National Institute on Drug Abuse; National Institue on Minority Health and Health Disparities
Posted on 5/25/17

Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33), RFA-AT-18-001, National Institutes of Health; National Center for Complementary and Integrative Health
Posted on 5/17/17

Tobacco Regulatory Science (R21), RFA-OD-17-009, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 5/10/17

Tobacco Regulatory Science Small Grant Program for New Investigators (R03), RFA-OD-17-008, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 5/10/17

Tobacco Regulatory Science (R01), RFA-OD-17-007, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 5/10/17

Genomic Community Resources (U24), PAR-17-273, National Institutes of Health; National Human Genome Research Institute; National Cancer Institute
Posted on 5/8/17

Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01), PAR-17-272, National Institutes of Health; National Institute of Mental Health
Posted on 5/4/17

Pilot Effectivness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34), PAR-17-271, National Institutes of Health; National Institute of Mental Health
Posted on 5/4/17

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (Collaborative R01), PAR-17-252, National Institutes of Health; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism
Posted on 4/11/17

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (R01), PAR-17-253, National Institutes of Health; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism
Posted on 4/11/17

Expanding Medication Assisted Treatment for Opioid Use Disorders in the Context of the SAMHSA Opioid STR Grants (R21/R33), RFA-DA-18-005, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/10/17

Extracellular Vesicles and Substance Use Disorders (R21), PAR-17-242, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/4/17

Extracellular Vesicles and Substance Use Disorders (R01), PAR-17-250, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/4/17

Center for Coordination of Analytics, Science, Enhancement , and Logistics (CASEL) in Tobacco Regulatory Science (U54), RFA-OD-17-002, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Institute on Drug Abuse; U.S. Food and Drug Administration, Center for Tobacco P
Posted on 3/13/17

Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54), RFA-OD-17-003, National Institutes of Health; U.S. Food and Drug Administration; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute
Posted on 3/13/17

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3), RFA-DA-18-003, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/8/17

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (Collaborative U01), PAR-17-176, National Institutes of Health; National Institute of Mental Health
Posted on 2/27/17

From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry (U01), PAR-17-179, National Institutes of Health; National Institute of Mental Health
Posted on 2/27/17

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R21), PA-17-157, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/8/17

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R01), PA-17-155, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/8/17

Basic Mechanisms of Brain Development Mediating Substance Use and Dependence (R01), PA-17-119, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 1/10/17

Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01), PA-17-120, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/10/17

Neuroscience Research on Drug Abuse (R21), PA-17-112, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/17

Neuroscience Research on Drug Abuse (R01), PA-17-111, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/17

NIDA Core Center of Excellence Grant Program (P30), PAR-17-121, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/17

2016

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01), RFA-MH-17-614, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34), RFA-MH-17-612, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01), RFA-MH-17-610, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33), RFA-MH-17-602, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01), RFA-MH-17-608, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33), RFA-MH-17-604, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33), RFA-MH-17-606, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33), RFA-MH-17-600, National Institutes of Health; National Institute of Mental Health
Posted on 12/13/16

NIH-DoD-VA Pain Management Collaboratory - Pragmatic Clinical Trials Demonstration Projects (UG3/UH3), RFA-AT-17-001, National Institutes of Health; Department of Defense; Department of Veterans Affairs; National Center for Complementary and Integrative Health; National Institute on Alcohol Abuse and Alcoholism; Eunice Kennedy Shriver National Institute of Child Health a
Posted on 12/12/16

Hepatitis C Virus (HCV) Advanced Molecular Detection in Support of Systems for Prevention, Treatment and Control of HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States (U24), RFA-DA-17-023, National Institutes of Health; Centers for Disease Control and Prevention; National Institute on Drug Abuse; National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention
Posted on 10/6/16

HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (UG3/UH3), RFA-DA-17-014, National Institutes of Health; Centers for Disease Control and Prevention; Substance Abuse and Mental Health Services Administration; Appalachian Regional Commission; National Institute on Drug Abuse; National Center for HIV/AIDS, Viral Hepatitis, STD and
Posted on 10/6/16

Drug Abuse Dissertation Research (R36), PA-16-443, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/22/16

Centers of Excellence in Genomic Science (CEGS) (RM1), PAR-16-436, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health
Posted on 9/19/16

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01), PAR-16-430, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/8/16

Grand Opportunity in Medications Development for Substance-Use Disorders (U01), PAR-16-431, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/8/16

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24), RFA-DA-17-019, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/7/16

NIDA Program Project Grant Applications (P01), PAR-16-393, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/5/16

Chemistry Science Track Award for Rapid Transition (C/START) (R03), PAR-16-383, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/1/16

Chemical Discovery (CHEM) Award (R21/R33), PAR-16-384, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/1/16

Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01), RFA-DA-17-013, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/28/16

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1), PAR-16-357, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/7/16

Ancillary Studies to Identify Behavioral and/or Psychological Phenotypes Contributing to Obesity (R01), PAR-16-304, National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention; Office of Behavioral and Social Sciences Research
Posted on 6/1/16

Reducing the Duration of Untreated Psychosis in the United States (R01), PAR-16-265, National Institutes of Health; National Institute of Mental Health
Posted on 5/17/16

Reducing the Duration of Untreated Psychosis in the United States (R34), PAR-16-264, National Institutes of Health; National Institute of Mental Health
Posted on 5/17/16

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01), PAR-16-234, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/10/16

Prescription Drug Abuse (R21), PA-16-232, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/10/16

Prescription Drug Abuse (R01), PA-16-233, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/10/16

Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research (R41/R42), RFA-DA-17-008, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/22/16

Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research (R43/R44), RFA-DA-17-009, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/22/16

Role of Astrocytes and Astrocytic Networks in Drug Abuse (R21), PA-16-145, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/22/16

Role of Astrocytes and Astrocytic Networks in Drug Abuse (R01), PA-16-144, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/22/16

The Application of Big Data Analytics to Drug Abuse Research (R01), PA-16-119, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/9/16

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3), RFA-DA-17-015, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/9/16

Services Planning Research in the Appalachian Region to Address Adverse Health Consequences Associated with Increased Opioid Injection Drug Use (R03), RFA-DA-16-015, National Institutes of Health; Appalachian Regional Commission; National Institute on Drug Abuse
Posted on 2/19/16

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21), PA-16-075, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/8/16

Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01), PA-16-076, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/8/16

Behavioral and Integrative Treatment Development Program (R03), PA-16-074, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 1/8/16

Behavioral and Integrative Treatment Development Program (R01), PA-16-072, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 1/8/16

Behavioral and Integrative Treatment Development Program (R34), PA-16-073, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 1/8/16

Behavioral Science Track Award for Rapid Transition (B/Start)(R03), PAR-16-071, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/8/16

2015

Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01), RFA-DA-16-012, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/14/15

Systems Biology Approaches in HIV/AIDS and Substance Use (R01), RFA-DA-16-013, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/10/15

Mechanism for Time-Sensitive Drug Abuse Research (R21), PAR-16-055, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/10/15

Seek, Test, Treat and Retain For Youth and Young Adults Living with or at High Risk for Acquiring HIV (R01), RFA-DA-16-010, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/8/15

Effects of Drugs of Abuse on Latent HIV Reservoirs in the CNS (R01), RFA-DA-16-014, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/8/15

Integration of Infectious Diseases and Substance Abuse Intervention Services for Individuals Living with HIV (R01), RFA-DA-16-011, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/7/15

Environmental Influences on Child Health Outcomes: Patient Reported Outcomes Research Resource Center Core (ECHO PRO Core) (U24), RFA-OD-16-003, National Institutes of Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Nationa
Posted on 12/7/15

Environmental Influences on Child Health Outcomes (ECHO) Pediatric Cohorts (UG3/UH3), RFA-OD-16-004, National Institutes of Health; National Cancer Institute; National Eye Institute; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Nationa
Posted on 12/7/15

NIDA Research Center of Excellence Grant Program (P50), PAR-16-009, National Institutes of Health; National Institute on Drug Abuse
Posted on 10/21/15

Major Opportunities for Research in Epidemiology of Alzheimer's Disease and Cognitive Resilience (R01), PAR-15-356, National Institutes of Health; National Institute on Aging
Posted on 9/24/15

AIDS-Science Track Award for Research Transition (R03), PA-15-290, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/9/15

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3), RFA-DA-16-008, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/21/15

Imaging - Science Track Award for Research Transition (I/START) (R03), PAR-15-326, National Institutes of Health; National Institute on Drug Abuse; National Institute of Biomedical Imaging and Bioengineering
Posted on 8/7/15

Tools for Monitoring and Manipulating Modified RNAs in the Nervous System (R43/R44), RFA-DA-16-005, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/21/15

Tools for Monitoring and Manipulating Modified RNAs in the Nervous System (R41/R42), RFA-DA-16-006, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/21/15

Data Coordinating Center for Sickle Cell Disease Implementation Consortium (SCDIC): Using Implementation Science to Optimize Care of Adolescents and Adults with Sickle Cell Disease (U24), RFA-HL-16-011, National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute on Minority Health and Health Disparities
Posted on 7/15/15

Extracellular Vesicles and Substance Abuse (R21), PAR-15-284, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/19/15

Extracellular Vesicles and Substance Abuse (R01), PAR-15-283, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/19/15

Longitudinal Assessment of Post -traumatic Syndromes (U01), RFA-MH-16-500, National Institutes of Health; National Institute of Mental Health
Posted on 6/12/15

Tools and Services for Designing Methodologically Rigorous Animal Studies (R41/R42), RFA-DA-16-002, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/4/15

Tools and Services for Designing Methodologically Rigorous Animal Studies (R43/R44), RFA-DA-16-003, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/4/15

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34), PA-15-268, National Institutes of Health; National Institute on Drug Abuse; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health
Posted on 5/28/15

Harnessing Genome Editing Technologies to Functionally Validate Genetic Variants in Substance Use Disorders (R21/R33), RFA-DA-16-004, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/27/15

Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3), PAR-15-267, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/26/15

Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R61/R33), RFA-MH-16-406, National Institutes of Health; National Institute of Mental Health
Posted on 5/22/15

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03), PA-15-252, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/8/15

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34), PA-15-250, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/8/15

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01), PA-15-251, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/8/15

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34), PA-15-250, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/8/15

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21), PA-15-253, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/8/15

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34), PA-15-177, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 4/7/15

Clinical Trials to Test the Effectiveness of Treatment, Preventive and Services Interventions (Collaborative R01), RFA-MH-16-415, National Institutes of Health; National Institute of Mental Health
Posted on 3/30/15

Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R33), RFA-MH-16-400, National Institutes of Health; National Institute of Mental Health
Posted on 3/30/15

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01), RFA-MH-16-420, National Institutes of Health; National Institute of Mental Health
Posted on 3/30/15

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01), RFA-MH-16-425, National Institutes of Health; National Institute of Mental Health
Posted on 3/30/15

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34), RFA-MH-16-410, National Institutes of Health; National Institute of Mental Health
Posted on 3/30/15

International Research Collaboration on Drug Abuse and Addiction Research (R21), PA-15-143, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/17/15

International Research Collaboration on Drug Abuse and Addiction Research (R01), PA-15-142, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/17/15

International Research Collaboration on Drug Abuse and Addiction Research (R03), PA-15-141, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/17/15

Identification of Genetic and Genomic Variants by Next-Gen in Sequencing Non-human Animal Models (U01), PAR-15-120, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/13/15

NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12), PAR-15-119, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/11/15

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01), RFA-DA-16-001, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/10/15

Gene-Environment Interplay in Substance Use Disorders (R21), PA-15-112, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 2/5/15

Gene-Environment Interplay in Substance Use Disorders (R03), PA-15-111, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 2/5/15

Gene-Environment Interplay in Substance Use Disorders (R01), PA-15-110, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 2/5/15

Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis and Informatics Center (U24), RFA-DA-15-016, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 2/4/15

Adolescent Brain Cognitive Development (ABCD) Study - Research Project Sites (U01), RFA-DA-15-015, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 2/4/15

Adolescent Brain Cognitive Development (ABCD) Study - Coordinating Center (U24), RFA-DA-15-014, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 2/4/15

Reductions in Illicit Drug Use and Functional Outcomes (R21/R33), PA-15-099, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/23/15

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3), RFA-DA-15-017, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/16/15

Drug Abuse Prevention Intervention Research (R21), PA-15-080, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/15

Drug Abuse Prevention Intervention Research (R03), PA-15-081, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/15

Drug Abuse Prevention Intervention Research (R01), PA-15-082, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/15

Identification of Genetic and Genomic Variants by Next-Gen in Sequencing Non-human Animal Models (U01), PAR-15-120, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/13/15

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01), RFA-DA-16-001, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/10/15

Gene-Environment Interplay in Substance Use Disorders (R21), PA-15-112, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 2/5/15

Gene-Environment Interplay in Substance Use Disorders (R03), PA-15-111, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 2/5/15

Adolescent Brain Cognitive Development (ABCD) Study - Data Analysis and Informatics Center (U24), RFA-DA-15-016, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental H
Posted on 2/4/15

Reductions in Illicit Drug Use and Functional Outcomes (R21/R33), PA-15-099, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/23/15

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UH2/UH3), RFA-DA-15-017, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/16/15

Drug Abuse Prevention Intervention Research (R01), PA-15-082, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/9/15

Children's Health Exposure Analysis Resource (CHEAR): Coordinating Center (U24), RFA-ES-15-011, National Institutes of Health; National Institute of Environmental Health Sciences
Posted on 2/26/15

2014

Epidemiology of Drug Abuse (R21), PA-15-001, National Institutes of Health; National Institute on Drug Abuse
Posted on 10/3/14

Epidemiology of Drug Abuse (R03), PA-15-002, National Institutes of Health; National Institute on Drug Abuse
Posted on 10/3/14

Epidemiology of Drug Abuse (R01), PA-15-003, National Institutes of Health; National Institute on Drug Abuse
Posted on 10/3/14

Enhancing Cross-National Research within the Health and Retirement Study Family of Studies (R01), RFA-AG-15-015, National Institutes of Health; National Institute on Aging
Posted on 7/30/14

Interventions for Youth who Misuse/Abuse Prescription Stimulant Medications in High School and/or College-Attending Youth (U01), RFA-DA-15-010, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/22/14

Extracellular Vesicles in HIV/AIDS and Substance Abuse (R21), RFA-DA-15-012, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/16/14

Extracellular Vesicles in HIV/AIDS and Substance Abuse (R01), RFA-DA-15-011, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/16/14

The National Drug Abuse Treatment Clinical Trials Network (UG1), RFA-DA-15-008, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/3/14

Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R33), PAR-14-231, National Institutes of Health; National Institute on Drug Abuse; National Institute of Mental Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/19/14

Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R21/R33), PAR-14-230, National Institutes of Health; National Institute on Drug Abuse; National Institute of Mental Health; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism
Posted on 5/19/14

Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01), PAR-14-225, National Institutes of Health; National Institute on Drug Abuse; National Center for Complementary and Integrative Health; National Cancer Institute
Posted on 5/15/14

Long-Term Retention in Care for U.S. Substance Using Populations (R01), PA-14-224, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/15/14

Long-Term Retention in Care for U.S. Substance Using Populations (R21), PA-14-223, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/15/14

Long-Term Retention in Care for U.S. Substance Using Populations (R34), PA-14-222, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/15/14

Centers of Excellence in Genomic Science (CEGS) (RM1), PAR-14-195, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health
Posted on 4/28/14

Epidemiology and Prevention in Alcohol Research (R01), PA-14-190, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
Posted on 4/24/14

Epidemiology and Prevention in Alcohol Research (R03), PA-14-189, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
Posted on 4/24/14

Epidemiology and Prevention in Alcohol Research (R21), PA-14-188, National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
Posted on 4/24/14

Genomic Resource Grants for Community Resource Projects (U41), PAR-14-191, National Institutes of Health; National Cancer Institute; National Human Genome Research Institute
Posted on 4/24/14

NIDA Core Center of Excellence Grant Program (P30), PAR-14-186, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/23/14

Effects of Cannabis Use and Cannabinoids on the Developing Brain (R01), PA-14-163, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/26/14

Effects of Cannabis Use and Cannabinoids on the Developing Brain (R21), PA-14-162, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/26/14

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01), PA-14-137, National Institutes of Health; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases
Posted on 3/3/14

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21), PA-14-136, National Institutes of Health; National Institute on Drug Abuse; National Institute of Diabetes and Digestive and Kidney Diseases
Posted on 3/3/14

Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34), PA-14-135, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/3/14

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01), PAR-14-106, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/20/14

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21), PAR-14-105, National Institutes of Health; National ?Institute on Drug Abuse
Posted on 2/20/14

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03), PAR-14-104, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/20/14

NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1), RFA-DA-15-004, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/13/14

Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01), RFA-DA-15-005, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/5/14

Neuroimmune Signaling in Substance Use Disorders (R01), PA-14-084, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/4/14

Neuroimmune Signaling and Function in Substance Use Disorders (R21), PA-14-083, National Institutes of Health; National Institute on Drug Abuse
Posted on 2/4/14

Medications Development Centers of Excellence Cooperative Program (U54), RFA-DA-15-003, National Institutes of Health; National Institute on Drug Abuse
Posted on 1/31/14

Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R01), PA-14-061, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 1/7/14

Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R21), PA-14-062, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 1/7/14

Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R03), PA-14-063, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 1/7/14

2013

Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R21), PA-14-036, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 12/12/13

Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03), PA-14-037, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 12/12/13

Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01), PA-14-038, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 12/12/13

Basic Mechanisms of Brain Development for Substance Use and Dependence (R01), PA-14-026, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 12/11/13

Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01), PA-14-025, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/10/13

Public Health Impact of the Changing Policy/Legal Environment for Marijuana (R01), PAS-14-020, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/6/13

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Abuse (R21), PA-14-013, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/5/13

Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Abuse (R01), PA-14-014, National Institutes of Health; National Institute on Drug Abuse
Posted on 12/5/13

Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM) (R21/R33), PAR-13-350, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/11/13

Neuroscience Research on Drug Abuse (R03), PA-13-336, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/26/13

Neuroscience Research on Drug Abuse (R21), PA-13-337, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/26/13

Neuroscience Research on Drug Abuse (R01), PA-13-338, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/19/13

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01), PAR-13-334, National Institutes of Health; National Institute on Drug Abuse
Posted on 8/19/13

Administrative Supplements to Promote Collaborative Research on Addiction at NIH (CRAN): Comorbidity-Related Research (Admin Supp), PA-13-275, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism
Posted on 7/15/13

Grand Opportunity in Medications Development for Substance-Use Disorders (U01), PAR-13-270, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/11/13

Seek, Test, Treat, and Retain Data Harmonization Coordinating Center (U01), RFA-DA-14-007, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/31/13

FY14 NIDA Avant-Garde Award Program for HIV/AIDS Research (DP1), RFA-DA-14-008, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/30/13

NIDA Research Center of Excellence Grant Program (P50), PAR-13-222, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/6/13

Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R01), RFA-DA-14-005, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/3/13

Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R21), RFA-DA-14-006, National Institutes of Health; National Institute on Drug Abuse
Posted on 5/3/13

Medications Development Centers of Excellence Cooperative Program (U54), RFA-DA-14-004, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/26/13

Centers of Excellence in Genomic Science (CEGS) (P50), PAR-13-198, National Institutes of Health; National Human Genome Research Institute; National Institute of Mental Health
Posted on 4/12/13

Drug Abuse Dissertation Research (R36), PAR-13-182, National Institutes of Health; National Institute on Drug Abuse
Posted on 4/5/13

Revision Applications to Promote Collaborative Research on Addiction at NIH (CRAN): Comorbidity-Related Research (R01), RFA-DA-14-014, National Institutes of Health; National Institute on Drug Abuse; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism
Posted on 7/15/13

NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12), PAR-13-163, National Institutes of Health; National Institute on Drug Abuse
Posted on 3/28/13

Prevention and Health Promotion Interventions to Prevent Alcohol and Other Drug Abuse and Associated Physical and Psychological Health Problems in U.S. Military Personnel, Veterans and their Families (R01), RFA-DA-13-012, National Institutes of Health; The Department of Defense; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of the Assistant Secretary of Defense for Health Affairs
Posted on 1/30/13

Prevention and Health Promotion Interventions to Prevent Alcohol and Other Drug Abuse and Associated Physical and Psychological Health Problems in U.S. Military Personnel, Veterans and their Families (R34), RFA-DA-13-013, National Institutes of Health; The Department of Defense; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Center for Complementary and Alternative Medicine; Office of the Assistant Secretary of Defense for He
Posted on 1/30/13

Behavioral & Integrative Treatment Development Program (R01), PA-13-077, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Center for Complementary and Integrative Health
Posted on 1/9/13

Behavioral & Integrative Treatment Development Program (R34), PA-13-078, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 1/9/13

Behavioral & Integrative Treatment Development Program (R03), PA-13-079, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; Office of Behavioral and Social Sciences Research
Posted on 1/9/13

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01), PAR-13-080, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; National Cancer Institute
Posted on 1/9/13

2012

Prescription Drug Abuse (R01), PA-13-015, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/2/12

Prescription Drug Abuse(R21), PA-13-016, National Institutes of Health; National Institute on Drug Abuse
Posted on 11/2/12

Drug Abuse Aspects of HIV/AIDS (R01), PA-12-293, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/25/12

Drug Abuse Aspects of HIV/AIDS (R03), PA-12-294, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/25/12

Drug Abuse Aspects of HIV/AIDS (R21), PA-12-295, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/25/12

HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21), PA-12-280, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/10/12

HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R01), PA-12-281, National Institutes of Health; National Institute on Drug Abuse
Posted on 9/10/12

Human Heredity and Health in Africa (H3Africa): Collaborative Centers (U54), RFA-RM-12-006, National Institutes of Health; This Funding Opportunity Announcement; Division of Program Coordination, Planning and Strategic Initiatives; Office of Strategic Coordination; National Human Genome Research Institute; Eunice Kennedy Shriver National Institu
Posted on 8/22/12

Human Heredity and Health in Africa (H3Africa): H3Africa Research Grants (U01), RFA-RM-12-007, National Institutes of Health; This Funding Opportunity Announcement; Division of Program Coordination, Planning and Strategic Initiatives; Office of Strategic Coordination; National Human Genome Research Institute; Eunice Kennedy Shriver National Institu
Posted on 8/22/12

Behavioral Science Track Award for Rapid Transition (B/START) (R03), PAR-12-251, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/26/12

Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21), PAR-12-238, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/16/12

Human Heredity and Health in Africa (H3Africa): H3Africa Research Grants (U01), PAR-12-239, National Institutes of Health; This Funding Opportunity Announcement; Division of Program Coordination, Planning and Strategic Initiatives; Office of Strategic Coordination; National Human Genome Research Institute; Eunice Kennedy Shriver National Institu
Posted on 8/22/12

Cohort Studies of HIV/AIDS and Substance Use (U01), PAR-12-222, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/6/12

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34), PA-12-231, National Institutes of Health; National Institute on Drug Abuse
Posted on 7/6/12

Research Education Grants for Statistical and Computational Training in the Genetics of Addiction (R25), PAR-12-199, National Institutes of Health; National Institute on Drug Abuse
Posted on 6/8/12

2011

Small Grants for Behavioral Research in Cancer Control (R03), PAR-12-035, National Institutes of Health; National Cancer Institute
Posted on 12/22/11

Gene-Environment Interplay in Substance Use Disorders (R21), PA-11-236, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 7/19/11

Gene-Environment Interplay in Substance Use Disorders (R03), PA-11-237, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 7/19/11

Gene-Environment Interplay in Substance Use Disorders (R01), PA-11-235, National Institutes of Health; National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism
Posted on 7/19/11

Personalized Genomics for Symptom Management: Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R01), RFA-NR-11-003, National Institutes of Health; National Institute of Nursing Research
Posted on 1/11/11

Personalized Genomics for Symptom Management: Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R21), RFA-NR-11-004, National Institutes of Health; National Institute of Nursing Research
Posted on 1/11/11

2010

The Electronic Medical Records and Genomics (eMERGE) Network, Phase II Coordinating Center (U01), RFA-HG-10-010, National Institutes of Health; National Human Genome Research Institute; The Electronic Medical Records and Genomics
Posted on 7/15/10

2009

Pharmacogenomics Research Network (U01/U19), RFA-GM-10-001, National Institutes of Health; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institute on Drug Abuse; National Institute on Mental Health; National Institute of Child Health
Posted on 1/30/09

2008

Genome-wide Association Studies of Treatment Response in Randomized Clinical Trials-Study Investigators (U01), RFA-HG-08-004, National Institutes of Health; National Human Genome Research Institute
Posted on 8/19/08

Genome-wide Association Studies of Treatment Response in Randomized Clinical Trials - Coordinating Center (U01), RFA-HG-08-005, National Institutes of Health; National Human Genome Research Institute
Posted on 8/19/08